Clinical Study Protocol  
 
Protocol Title:  A Phase II Randomized, Double -Blind, 
Placebo -Controlled,  Study of LAM -002A 
for the Prevention of Progression of  
COVID -19 
Protocol Number:  LAM-002A -CVD -CLN0 1 
Protocol Date:  16 October 2020  
NCT:  NCT0444637 7 
 
 
CONFIDENTIAL  Page 1 of 91  Version 4 (16 October  2020)   
Clinical Study Protocol  
Protocol Title  A Phase II Randomized, Double-Blind, Placebo-Controlled, 
Study of LAM -002A for the Prevention of Progression of 
COVID-19 
Study Sponsor  AI Therapeutics, Inc.  
530 Old Whitfield St Guilford CT, 06437 
Investigational Product  LAM -002A 
Protocol Number  LAM -002A-C VD-CLN01  
Developmental Phase  Phase II  
US IND Number  148521 
Protocol Versions (Date)  Version 1 (22 June 2020) Version 2 (10 July 2020) Version 3 (31 August 2020) Version 4 ( 16 October 2020) 
  
Confidentiality Statement 
This document contains confidential information belonging to AI Therapeutics, Inc. Except as may be 
otherwise permitted in writing, by accepting or reviewing these materials, it is agreed that this 
information should not be disclosed to others (except if required by applicable law or regulation) and 
should not be used for unauthorized purposes.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 2 of 91  Version 4 (16 October  2020)  Study Personnel  
Information regarding sponsor-designated study personnel are described in the Pharmacy 
Manual . 
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 3 of 91  Version 4 (16 October  2020)  AI Therapeutics, Inc. Approval Page 
Title  A Phase II Randomized, Double- Blind , Placebo -Controlled, Study 
of LAM -002A for the Prevention of Progression of COVID-19. 
Protocol Number  LAM -002A-C VD-CLN01  
Version  (Date)  Version 4 (16 October 2020) 
By signing this document, it is confirmed on behalf of AI Therapeutics, Inc., that this study 
will be conducted and reported in compliance with the protocol, accepted standards of Good Clinical Practice (GCP), and all applicable regulatory requirements. 
 
  
16 October 2020 
Langdon L Miller, MD  
Clinical Advisor  
AI Therapeutics, Inc.   Date  
 

Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 4 of 91  Version 4 (16 October  2020)  Principal Investigator Approval Page 
Title  A Phase II Randomized, Double- Blind , Placebo -Controlled, Study of 
LAM -002A for the Prevention of Progression of COVID-19  
Protocol Number  LAM -002A-C VD-CLN01  
Version (Date)  Version 4 (16 October 2020) 
I have reviewed the protocol. On behalf of my institution, I agree to conduct the study as 
outlined in the study protocol and in compliance with Good Clinical Practices (GCP) and all applicable regulatory requirements.  
 
   
Principal Investigator Signature   Date  
   
Principal Investigator Printed Name    
Institution:   
Address:   
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 5 of 91  Version 4 (16 October  2020)  Table of Contents  
1. PROTOCOL SYNOPSIS AND SCHEDULE OF 
ACTIVITIES  .................................................................................................................14  
2. INTRODUCTION  ........................................................................................................21  
2.1. Study Rationale ...............................................................................................................21  
2.2. Background .....................................................................................................................22  
2.2.1.  LAM -002A Mechanism of Action ..................................................................................22  
2.2.2.  Human Experience with LAM-002A ..............................................................................22  
2.3. Benefit/Risk Assessment  ................................................................................................23  
3. STUDY OBJECTIVES  ................................................................................................25  
3.1. Primary Objective  ...........................................................................................................25  
3.2. Secondary Objectives  .....................................................................................................25  
3.2.1.  Safety and Tolerability  ....................................................................................................25  
3.2.2.  Clinical Efficacy  .............................................................................................................25  
3.2.3.  Clinical Status  .................................................................................................................25  
3.2.4.  Oxygen Saturation ..........................................................................................................25  
3.3. Exploratory Objectives  ...................................................................................................26  
3.3.1.  Pharmacokinetic  ..............................................................................................................26  
3.3.2.  Viral Clearance  ...............................................................................................................26  
3.3.3.  Pharmacodynamic Objectives  .........................................................................................26  
3.3.4.  Genetic Evaluation Objectives ........................................................................................26  
4. STUDY ENDPOINTS  ..................................................................................................27  
4.1. Primary Endpoint ............................................................................................................27  
4.2. Secondary Endpoints ......................................................................................................27  
4.2.1.  Safety and Tolerability  ....................................................................................................27  
4.2.2.  Clinical Efficacy  .............................................................................................................27  
4.2.3.  Clinical Status  .................................................................................................................27  
4.2.4.  Oxygen Saturation ..........................................................................................................27  
4.3. Exploratory Endpoints  ....................................................................................................28  
4.3.1.  Pharmacokinetics  ............................................................................................................28  
4.3.2.  Viral Clearance ...............................................................................................................28  
4.3.3.  Pharmacodynamics .........................................................................................................28  
4.3.4.  Immunogenicity Endpoints .............................................................................................28  
4.3.5.  Genetic Endpoints ...........................................................................................................28  
5. STUDY DESIGN AND CONDUCT  ............................................................................30  
5.1. Study Design ...................................................................................................................30  
5.2. Study Conduct.................................................................................................................30  
5.3. Rationale for Study Design .............................................................................................31  
5.4. Justification for Dose  ......................................................................................................32  
6. STUDY POPULATION ...............................................................................................35  
6.1. Inclusion Criteria  ............................................................................................................35  
6.2. Exclu sion Criteria  ...........................................................................................................36  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 6 of 91  Version 4 (16 October  2020)  7. STUDY DRUG ALLOCATION  ..................................................................................38  
7.1. Randomization ................................................................................................................38  
7.2. Blinding ..........................................................................................................................38  
8. STUDY DRUG INFORMATION, ADMINISTRATION, 
AND SUPPORT ............................................................................................................39  
8.1. Blinded Study Drug (LAM-002A and Placebo) .............................................................39  
8.1.1.  Description  ......................................................................................................................39  
8.1.2.  Source .............................................................................................................................39  
8.1.3.  Packaging and Labelling .................................................................................................39  
8.1.4.  Shipping, Storage, and Stability......................................................................................39  
8.1.5.  Dispensing.......................................................................................................................39  
8.1.6.  Return and Compliance Assessment  ...............................................................................39  
8.1.7.  Accountability .................................................................................................................40  
8.1.8.  Overdose Precautions ......................................................................................................40  
8.1.9.  Inadvertent Exposure Precautions  ...................................................................................40  
8.2. Study Drug Administration .............................................................................................40  
8.2.1.  Drug Administration  .......................................................................................................40  
8.2.2.  Fed/Fasting Status  ...........................................................................................................41  
8.2.3.  Dose Schedule Interruptions and Vomited Doses ..........................................................41  
8.2.4.  Dose Modification Recommendations  ............................................................................41  
8.3. Emergency Unblinding  ...................................................................................................42  
8.4. Supportive Care  ..............................................................................................................42  
8.4.1.  General Recommendations  .............................................................................................42  
8.4.2.  Antibiotics, Antifungals, and Antivirals .........................................................................42  
8.4.3.  Anti-SARS -CoV-2 Therapies .........................................................................................43  
8.4.4.  Anticoagulants ................................................................................................................43  
8.4.5.  Antidiarrheals  ..................................................................................................................43  
8.4.6.  Antiemetics  .....................................................................................................................43  
8.4.7.  Antihistamine, Antiinflammatory, or Antipyretic, Drugs  ...............................................44  
8.4.8.  Corticosteroids  ................................................................................................................44  
8.4.9.  Drugs with Drug-Drug Interaction Potential ..................................................................44  
8.4.10.  Drugs Known to Prolong the QT Interval .......................................................................44  
8.4.11.  Hematopoietic Support ...................................................................................................44  
8.4.12.  Cardiopulmonary Support ...............................................................................................44  
8.5. Study Restrictions ...........................................................................................................45  
8.5.1.  Breast Feeding  ................................................................................................................45  
8.5.2.  Contraception/Reproduction ...........................................................................................45  
8.5.3.  Diet ..................................................................................................................................46  
8.6. Duration of Study Drug Administration and Study Participation ..................................46  
9. SAFETY ASSESSMENT  .............................................................................................47  
9.1. Definitions  ......................................................................................................................47  
9.1.1.  Adverse E vent .................................................................................................................47  
9.1.2.  Serious Adverse Event  ....................................................................................................48  
9.1.3.  Unexpected Adverse Event  .............................................................................................48  
9.1.4.  Treatment -Emergent Adverse Event  ...............................................................................49  
9.1.5.  Adverse Events of Special Interest  .................................................................................49  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 7 of 91  Version 4 (16 October  2020)  9.2. Eliciting Adverse Event Information  ..............................................................................49  
9.3. Recording Adverse Events ..............................................................................................49  
9.4. Grading of the Severity of an Adverse Event .................................................................50  
9.5. Describing Adverse Event Relationship to Study Drug and Study 
Procedures .......................................................................................................................50  
9.6. Adverse Event Reporting Period ....................................................................................51  
9.7. Study Center Reporting Requirements ...........................................................................51  
9.7.1.  Adverse Event Reporting Requirements .........................................................................51  
9.7.2.  Pregnancy ........................................................................................................................53  
9.7.3.  Contact Information for Reporting an SAE or Pregnancy  ..............................................54  
9.8. Sponsor Reporting Requirements ...................................................................................54  
10. LABORATORY AND OTHER ASSESSMENTS  .....................................................55  
10.1.  Methods and Analytes ....................................................................................................55  
10.2.  Sample Shipping, Storage, and Retention ......................................................................56  
11. EFFICACY ASSESSMENTS  ......................................................................................58  
11.1.  Primary Efficacy Endpoint: Viral Clearance at Day 4  ...................................................58  
11.2.  Secondary Efficacy Endpoint .........................................................................................58  
11.2.1.  Clinical Efficacy  .............................................................................................................58  
11.2.2.  Hospitalization: Clinical Status .......................................................................................60  
12. STATISTICAL CONSIDERATIONS  ........................................................................62  
12.1.  Statistical Hypotheses  .....................................................................................................62  
12.2.  Sample Size Determination  ............................................................................................62  
12.3.  Analysis Sets ...................................................................................................................63  
12.3.1.  Intention to Treat (ITT) Population  ................................................................................63  
12.3.2.  Antiviral Efficacy Analysis Population ..........................................................................63  
12.3.3.  Per Protocol (PP) Population  ..........................................................................................63  
12.3.4.  Safety Population ............................................................................................................63  
12.4.  Statistical Analyses  .........................................................................................................63  
12.4.1.  General Considerations  ...................................................................................................63  
12.4.2.  Comparability of Baseline Characteristics. .....................................................................63  
12.4.3.  Analysis of Primary Outcome: Viral Load in Nasopharyngeal Samples at Day 4  ............................................................................................................64
 
12.4.4.  Analysis of Secondary Outcomes  ...................................................................................64  
12.4.5.  Exploratory Endpoints  ....................................................................................................65  
12.4.6.  Subgroup Analyses .........................................................................................................65  
12.4.7.  Plan for Missing Data  .....................................................................................................65  
12.4.8.  Safety and Tolerability Analyses  ....................................................................................65  
12.4.9.  Other Safety Analyses  .....................................................................................................67  
12.5.  Interim Analyses  .............................................................................................................67  
13. STUDY ADMINISTRATION AND RESPONSIBILTIES  .......................................68  
13.1.  General Investigator Responsibilities  .............................................................................68  
13.2.  Protocol Compliance.......................................................................................................68  
13.3.  Compliance with Ethical and Regulatory Guidelines .....................................................68  
13.4.  Institutional Review Board/Independent Ethics Committee (IRB/IEC) ........................................................................................................................69
 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 8 of 91  Version 4 (16 October  2020)  13.5.  Informed Consent ...........................................................................................................70  
13.6.  Confidentiality  ................................................................................................................70  
13.7.  Study Files and Retention of Records and Biological Samples......................................71  
13.8.  Subject Screening Log ....................................................................................................72  
13.9.  Modifications of the Protocol or Informed Consent Documents  ....................................72  
13.10.  Case Report Forms ..........................................................................................................72  
13.11.  Study Drug Accountability .............................................................................................73  
13.12.  Monitoring ......................................................................................................................74  
13.13.  Inspectio ns ......................................................................................................................74  
13.14.  Data Management  ...........................................................................................................74  
13.15.  Clinical Trial Insurance  ..................................................................................................75  
13.16.  Communications with Regulatory Authorities  ...............................................................75  
13.17.  Public Notification of Study Conduct .............................................................................75  
13.18.  Study Reporting and Publication ....................................................................................75  
13.19.  Study Discontinuation.....................................................................................................76  
14. BIBLIOGRAPHY  .........................................................................................................77  
15. APPENDICES  ...............................................................................................................79  
15.1.  Strong CYP3A Inhibitors and Inducers ..........................................................................79  
15.2.  Drugs Known to Prolong the QT Interval and/or Cause Torsades 
De Pointes .......................................................................................................................80  
15.3.  ECOG Performance Status  .............................................................................................84  
15.4.  Protocol Amendment History  .........................................................................................85  
15.4.1.  Summary of Changes: Version 2 (10 July 2020) ............................................................85  
15.4.2.  Summary of Changes: Version 3 (31 August 2020) .......................................................87  
15.4.3.  Summary of Changes: Version 4 ( 16 October  2020) ......................................................89  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 9 of 91  Version 4 (16 October  2020)  LIST OF TABLES  
Table  1: Schedule of Activities  ....................................................................................... 18  
Table 2.  Summary of LAM -002A In Vitro Activity Against SARS CoV-2 ................... 34  
Table 3.  Grading of Adverse Event Severity .................................................................. 50  
Table 4.  Relationship of Study Drug to Adverse Event .................................................. 51  
Table 5.  Study Center Reporting Requirements for Adverse Events .............................. 52  
Table 6.  Laboratory and Other Parameters to Be Assessed  ............................................ 56  
Table 7  National Early Warning Score (NE WS) ........................................................... 60  
Table 8.  Death Boundary for Study Termination ............................................................ 67  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 10 of 91  Version 4 (16 October  2020)  LIST OF ABBREVIATIONS  
Abbreviation  Definition  
AE Adverse event  
ALT  Alanine aminotransferase  
ANCOVA  Analysis of covariance  
API Active pharmaceutical ingredient  
AST  Aspartate aminotransferase  
AUC 0-t Area under the plasma concentration versus  time curve, as determined by a trapezoidal 
method, from time zero to t hours post- dose 
AUC 0-24 Area under the curve 0 -24 hours  
AVPU  Alert, voice, pain, unresponsive  
βHCG  Beta human chorionic gonadotropin  
BID Twice per day 
BIPAP  Bilevel Positive Airway Pressure  
BTK  Bruton tyrosine kinase  
BUN  Blood  urea nitro gen 
CFR  Code of Federal Regulations  
cGMP  Current Good Manufacturing Practices  
CK Creatine kinase  
CLIA  Clinical Laboratory Improvement Amendments  
Cmax Maximal plasma concentration  
CMC  Chemical Manufacturing and Control  
CNS  Central Nervous System  
COA  Certificate of Analysis  
COVID  Corona virus Disease  
CRF  Case Report Form  
CRO  Clinical research organization  
CTCAE  Common Terminology Criteria for Adverse Events  
CV Cardiovascular  
CYP3A4  Cytochrome P450 3A4  
DNA  Deoxyribonucleic acid  
DSMB  Data and Safety Monitoring Board  
EBV  Ebola virus  
ECG  Electrocardiogram  
eCLCR  Estimated creatinine clearance  
ECMO  Extracorporeal membrane oxygenation  
ECOG  Eastern Cooperative Oncology Group  
eCRF  Electronic Case Report Form  
EDC  Electronic data system  
ELISA  Enzyme -linked immunosorbent assay  
FDA  Food and Drug Administration  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 11 of 91  Version 4 (16 October  2020)  Abbreviation  Definition  
FSH Follicle -stimulating hormone  
GCP  Good clinical practice  
GLP  Good Laboratory Practice  
GP Glycoprotein  
h or hr  Hour  
HDPE  High density polyethylene  
HEPA  High -efficiency particulate air  
HET  Heterogeneity of treatment effect  
HIV Human immunodeficiency virus  
HPLC  High -performance liquid chromatography  
IC50 Inhibitory Concentration 50%  
ICH International Conference on Harmonization  
ICU Intensive care unit  
IEC Independent ethics committee  
IFNγ Interferon gam ma 
IIG Inactive Ingredient  
IL6 Interleukin 6  
IL-10 Interleukin 10  
IL-12 Interleukin 12  
IL-23 Interleukin 23  
IND Investigational New Drug  
IRB Institutional Review Board  
ITT Intent to treat  
IUD Intrauterine device  
IUS Intrauterine hormone -releasing system  
IV Intravenous  
LDH  Lactate dehydrogenase  
MARV  Marburg virus  
MedDRA  Medical Dictionary for Regulatory Activities  
MERS  Middle East respiratory syndrome  
MERS -CoV  Middle East respiratory syndrome coronavirus  
mg/kg  Milligram/kilogram  
mg/kg/day  Microgram/kilogram/day  
μg Microgram  
MH Mantel -Haenszel  
μg/mL  Microgram per milliliter  
mL Milliliter  
mL/kg  Milliliter/kilogram  
Msec  Millisecond  
n Number of Observations  
NCI CTCAE  National Cancer Institute Common Terminology Criteria for Adverse Events  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 12 of 91  Version 4 (16 October  2020)  Abbreviation  Definition  
NDA  New Drug Application  
NEWS  National Early Warning Score  
NHL  Non-Hodgkins Lymphoma  
NIOSH  National Institute for Occupational Safety and Health  
nM Nanomolar  
NPCI  Niemann -Pick C1  
NSAID  Nonsteroidal anti -inflammatory drugs  
PAPR  Powered air -purifying respirator  
PBMC  Peripheral blood mononuclear cells  
PCR  Polymerase chain reaction  
PI Phosphatidylinositol  
PI3P  Phosphatidylinositol 3 -phosphate  
PIKfyve  Phosphatidylinositol -3-phosphate - 5 kinase  
PK  Pharmacokinetics  
pM Pico molar  
PO Per os (by mouth)  
PP Per protocol  
PPE Personal protective equipment  
QD Once a day  
QRS  Combination of three of the graphical deflections seen on a typical electrocardiogram (ECG)  
QT Time of start of Q wave until end of T wave in the heart’s electrical cycle  
QTc Corrected QT  
QTcF  QTc by Fridericia  
RBC  Red blood cell  
RNA  Ribonucleic acid  
RNAseq  RNA sequence analysis  
RR Respiratory rate, also risk ratio  
RT-PCR  Reverse transcriptase polymerase chain reaction  
SAC  Staphylococcus aureus Cowan I strain  
SAE  Series Adverse Event  
SAP Statistical Analysis Plan  
SARS  Severe acute respiratory syndrome  
SARS -CoV  Severe acute respiratory syndrome corona virus  
SD Standard Deviation  
SoA Schedule of activities  
SUSAR  Suspected unexpected serious adverse reactions  
T 1/2  Elimination half -life 
TBD  To be determined  
TdP Torsades de Pointes  
TEAE  Treatment Emergent Adverse Event  
TFEB Transcription Factor EB  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 13 of 91  Version 4 (16 October  2020)  Abbreviation  Definition  
Th1 T-helper lymphocyte type 1  
TLR  Toll-like receptor  
TLS Tumor Lysis Syndrome  
Tmax Time to maximum concentration  
UK United Kingdom  
US United States  
vs. Versus  
 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 14 of 91  Version 4 (16 October  2020)  1. PROTOC OL SYNOPSIS AND SCHEDULE OF ACTIVITIES  
Study Title  A Phase II Randomized, Double-Blind, Placebo- controlled , Study of 
LAM -002A for the Prevention of Progression of COVID-19  
Study Number  LAM -002A-C VD-CLN01  
Investigational 
Medicinal Product  LAM -002A (Apilimod dimesylate capsules)  
Clinical Phase  Phase II  
Sponsor  AI Therapeutics, Inc.  
530 Old Whitfield Street  
Guilford, Connecticut 06437 
Study Objective(s)  
Primary Objective : 
• To evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 with a 
baseline viral load >105 copies/mL as measured by SARS -CoV -2 clearance as determined 
by a quantitative RT- PCR  (qRT -PCR ) test from nasopharyngeal samples at Day  4 
(72 hours ± 4 hours after the first dose of the study drug). 
Secondary Objective(s) : 
• To evaluate the safety and tolerability of LAM -002A administration in the treatment of 
subjects with mild COVID-19. 
• To evaluate the efficacy of LAM -002A in preventing COVID-19 disease progression in 
subjects who have proven infection with the SARS -CoV-2 virus as determined by a 
validated  test; disease progression is defined as the occurrence of any of the following:  
o Death at Day  28 
o Hospitalization at Day  28 
• To evaluate change in COVID-19 clinical status , as defined by the ordinal scale, of 
subjects treated with LAM -002A compared to placebo at Day 28, in subjects who become 
hospitalized and continue LAM -002A /placebo treatment.  
• To compare the proportion of subjects at or above 95% oxygen saturation (O 2 sat) between 
LAM -002A  versus placebo treatment  groups as measured on Days 1, 4, and 11.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 15 of 91  Version 4 (16 October  2020)  Exploratory Objective(s) :  
• To potentially evaluate the pharmacokinetics of LAM -002A in subjects with mild 
COVID-19. 
• To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 
with a baseline viral load >105 copies/mL as measured by SARS -CoV- 2 clearance as 
determined by qRT -PCR  test from saliva samples at Day 4. 
• To potentially evaluate the antiviral efficacy o f LAM -002A in subjects with COVID -19 
with a baseline viral load >105 copies/mL  as measured by SARS -CoV-2 clearance as 
determined by a qRT -PCR test  from saliva samples at Day 11. 
• To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 
with a baseline viral load >105 copies/mL  as measured by SARS -CoV-2 clearance as 
determined by a qRT -PCR test  from saliva samples  at Day 28. 
• To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 
with a baseline viral load >105 copies/mL as measured by SARS- CoV- 2 clearance as 
determined by a qRT -PCR test  from saliva samples at all available days based on AUC 
analysis.  
• To potentially evaluate the difference in proportion of subjects with a SARS -CoV- 2 viral 
load <LLOQ between the LAM-002A and the placebo arm as measured by a qRT -PCR 
test from nasopharyngeal samples at Day 4. 
• To potentially evaluate the effect of LAM -002A on target engagement biomarkers . 
• To potentially evaluate the effect of LAM -002A on pro- and anti -inflammatory cytokine 
levels and target engagement biomarkers in COVID-19 subjects. 
• To potentially evaluate viral resistance by comparing genomic sequence of SARS -CoV -2 
before and after LAM -002A treatment. 
• To potentially evaluate the effect of SARS -CoV-2 genetic variants on LAM -002A 
efficacy . 
• To potentially evaluate the effect of germline DNA sequence polymorphisms on 
LAM -002A  safety and efficacy . 
Study Design:  
This is a Phase II randomized, double-blind, placebo- controlled, clinical study to evaluate  the 
efficacy of  LAM -002A compared to placebo treatment  in adults with a confirmed 
SARS -CoV-2 infection who are receiv ing standard supportive care in an outpatient setting .  
Study eligibility will be assessed during screening. All study participants must sign a written  
informed consent and satisfy the inclusion and exclusion criteria for the study. Written 
documentation confirm ing SARS -CoV-2 infection via a validated test , medical history, and 
current medication will be assessed for each consenting participant at screening.  
Study participants will be randomiz ed in a 1:1 ratio, to receive study therapy (either 
LAM -002A, 125 mg [5 capsules/dose] ) PO BID or placebo [ 5 capsules /dose] PO BID) for 
10 days. Nasopharyngeal swabs for quantification of baseline viral load  will be performed  on 
Day 1 , however, results will not be available before administration of treatment. Subjects who 
experience a n AE considered to be related to study therapy may have a decrease in study dose 
to LAM -002A , 100 mg [4 capsules/dose]) PO BID or placebo [ 4 capsules/dose] PO BID) . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 16 of 91  Version 4 (16 October  2020)  After the start of treatment on Day 1, subjects  will be followed  at Days 4, 6, 8, 11, 22, and 2 8. 
Subjects can withdraw from the study therapy or study participation at any time. 
The study will incorporate an interim safety analysis after the first 30 subjects (15 on 
LAM -002A and 15 on placebo) have completed treatment and have been followed up for 
11 days post-first dose. Recruitment and randomization will continue while this analysis is 
conducted. An additional interim analysis will be conducted at 50% of total enrollment.  
Recruitment and randomization will continue while this analysis is conducted. 
Recommendations from an independent DSMB will be used for decision of early termination 
or design adaptations. 
Primary analysis of antiviral efficacy will be conducted in the su bgroup of randomized 
participants with a baseline viral load > 105 copies/mL . As existing data on viral load is 
preliminary , this baseline may be adjusted as detailed in the statistics section. Non -parametric 
and parametric statistical analysis will be conducted as appropriate . For the comparison of the 
LAM -002A active arm and the control arm  for the primary endpoint and secondary endpoints 
of drug effect, appropriate methods will be employed. Baseline subject characteristics, study 
therapy administratio n/compliance, safety, supportive care administration, and 
pharmacokinetics will be analyzed descriptively.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 17 of 91  Version 4 (16 October  2020)  Product Description:  
LAM -002A (apilimod dimesylate) is a first- in-class inhibitor of phosphatidylinositol-3-
phosphate 5- kinase (PIKfyve)  that has demonstrated in vitro  anti-viral activity against 
SARS -COV -2 infected cells .  
Each Size 0 capsule of the active drug contains 25 mg of LAM -002A (equivalent to 17.1 mg 
of apilimod free base). Inactive components in the capsules are microcrystallin e cellulose, 
silicified microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, colloidal 
silicon dioxide, and magnesium stearate.  
Each Size 0 capsule of the placebo is identical in appearance to capsules containing the active 
drug.  Each pl acebo capsules contain s microcrystalline cellulose as the inactive ingredient . 
All inactive excipients are within the limits of FDA’s Inactive Ingredient (IIG) limit 
requirements.  
Study Activities:  
The specific study procedures and timing of activities to be conducted for each subject enrolled in the study are presented in tabular form in Table  1. Physical examinations, other 
clinical evaluations, and additional laboratory studies or more frequent assessments may be 
performed consistent with appropriate medical care for the subject, but these data will not 
necessarily be collected unless specified  in Table  1.  
Missed or delayed procedures or evaluations should be performed as close to the originally 
scheduled date/time as possible. Based on the medical monitor’s judgment, an exception can 
be made when rescheduling becomes medically unnecessary because it is too close in time to 
the next scheduled procedure or evaluation. In that case, the missed evaluation may be omitted after consultation with the medical monitor.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc. 
CONFIDENTIAL  Page 18 of 91  Version 4 (14  October 2020)  Table  1: Schedule of Activities  
Procedures Screening  
[a] Intervention Period  
 [Days]  Follow -up 
Period [Days]  
Early 
Termi-
nation  1 2 3 4 5 6      
Phone 
Visit 7 8         
Phone 
Visit 9 10 11 22        
Phone 
Visit 28 
Visit Day s 
(Window)   [b]   (72 
hours ± 
4 hours)         (±2) (±2) 
General Eligibility/Safety Assessments                 
Informed consent [ c] X               
Enrollment criteria [ d] X               
Demograph ics [e] X               
Medical  history [ f] X               
ECOG performance status [ g] X               
Height, weight [ h] X               
Vital signs/oxygen saturation (NEWS) [ i] X X   X  X  X   X  X X 
AE review [ j] X X   X  X  X   X X X X 
Concomitant medication review [ k] X X   X  X  X   X X X X 
12-lead ECG [ l] X               
Enrollment, Randomization, Study Drug Administration                
Submit randomization form [ m] X X              
Study drug administration in clinic [ n]  X              
Dispensing of study drug [ o]  X              
Self-administration of study drug by subject [ p]  X X X X X X X X X X     
LAM -002A  return/compliance and diary check [ q]     X  X  X   X   X 
Laboratory/Disease Assessments                 
Patient COVID -19 symptom s diary completed  (r) X X X X X X X X X X X X X X X 
Serum or urine pregnancy test [ s] X               
Blood for DNA and RNA isolation [ t] X               
Nasopharyngeal swabs for viral load analysis  and infectious disease diagnostic 
(Biofire or equivalent) [ u]  X   X           
Saliva for SARS -CoV -2 viral load, sequence, and target engagement analysis  [v]  X   X       X  X  
Blood for hematology [ w] X           X   X 
Serum chemistry [ x] X           X   X 
Blood for cytokine analysis/target engagement [ y]  X   X       X    
Plasma for pharmacokinetics [ z]  X          X    
Secondary clinical endpoint assessment [ aa]              X  
See footnotes on next page   
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc. 
CONFIDENTIAL  Page 19 of 91  Version 4 (14  October 2020)  Table  1: Schedule of Activities  
Footnotes:   
Note: For pharmacokinetic assessments to be performed at specified times postdose  on Day 1, the acceptable margin for actual time is as follows for hours (± minutes): 1 (±15) 
and 2  (±15). For scheduled visits after Day 1, permitted visit windows are indicated in the table.  
a. The screening and baseline visits can occur on the same day. Day 1 of the study is the day the subject takes the first dose of study drug after randomization.  
b. Hematology and serum chemistry collected during Screening need not be repeated on Day  1. 
c. Writte n informed consent will be obtained before performance of any study procedures that are not part of routine medical care.  
d. Adverse changes in inclusion/exclusion criteria before randomization should be discussed with the medical monitor before rand omizatio n. Optional confirmatory SARS CoV -2 
rapid viral test for patients who do not have documentation of positive infection. These rapid SARS CoV -2 viral tests will be supplied by the site and only conducted after the ICF 
is signed.  
e. Demograph ics to include sex, age, race, ethnicity.  
f. Medical history to include recording of COVID -19 history, previous therapy for COVID -19, past and ongoing medical conditions, substance use (smoking, alcohol), and 
cardiovascular history.  
g. Performance status will be assessed at Screening using the ECOG scale:  Grade 1 : Fully active, able to carry on all pre -disease performance without restriction; Grade 2 : Restricted 
in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work; Grade 3 : Ambulatory and capable of all 
self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; Grade 4: Capable of only limited self -care; confined to bed or chair more t han 
50% of waking hours; completely disabled. Cannot carry on any self -care; totally confined to bed or chair.  
h. Height (in centimeters) and weight (in kilograms) will be obtained at Screening only.  
i. Vital signs (respiratory rate, blood pressure, pulse, te mperature, and oxygen saturation via pulse oximetry) will be obtained with the subject resting in a seated upright position 
while breathing room air or with supplemental oxygen (if required). National Early Warning Score (NEWS) score will be derived  from respiratory rate, oxygen saturation, 
supplemental oxygen use , temperature, systolic blood pressure, heart rate, and AVPU (alert, voice, pain, unresponsive). Assessments will be performed on Day 1 (predose), Day 4, 
Day 11  and Day 28 during site visits . 
j. AEs will be described using concise medical terminology, including whether the AE is serious, the date of AE onset, the date of A E resolution, the severity of the AE based on the 
CTCAE, Version 5.0, a description of relatedness of the AE to study drug or to a study procedure, the action taken due to the AE, and the outcome of the AE. AEs will be collected 
beginning once ICF is executed and include any changes from medical history.  Day 6, Day 8 , and Day 22 assessments will be done via telephone  
k. Concomitant med ication assessments should include information regarding all prescription, nonprescription, and alternative medications (heal th foods). Use of any other drugs 
intended as therapy for COVID-19 (e.g. antivirals, antimalarials, BTK inhibitors, anti-IL-6 antib odies) or supportive care (e.g. antidiarrheals, NSAIDs, antiemetics, supplemental 
oxygen) should be noted. Information on concomitant medications used during Screening or since the last assessment will be as sessed on each designated day. Day 6, 8, and 22 
assessments will be done via telephone  
l. 12-lead ECG will be obtained with the subject resting in a supine position at Screening. An ECG obtained within 30 days prior to  the Screening visit is acceptable.  
m. At Screening, obtain a subject number.  On Day 1, randomize the subject and obtain a study drug bottle number.  
n. The first dose of blinded study drug ( LAM -002A  or placebo) will be administered to the subject in the study center (with recording of the date and actual clock time of the 
LAM -002A  administratio n). Depending on the time of administration (AM vs PM), the follow -up visit times will be determined as AM or PM.  
o. Study personnel will dispense the remainder of the 10 -day supply of blinded study drug ( LAM -002A  or placebo) to the subject with instructions for self -administration at home.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc. 
CONFIDENTIAL  Page 20 of 91  Version 4 (14  October 2020)  Table  1: Schedule of Activities  
p. Study subjects will be given the blinded study drug ( LAM -002A  or placebo) after randomization and will self -administer continuously thereafter until the evening of Day 10 or th e 
morning of Day 11 (20 total doses) depending on if the first dose is taken in the AM or PM on Day 1. On Day 1, subjects should ingest the study drug (LAM-002A or placebo) 
while fasting (defined as no food with the exception of clear liquids for ≥2 hours before and ≥1  hour after dosing). With other doses, subjects may take the study drug without 
regard to fed or fasting status , However, subjects should be advised to avoid ingestion of grapefruit, grapefruit juice, or Seville oranges , and should not use St. John’s wort . 
Subjects should take the study drug at approximately the same time each day, ideally at ~12-hour intervals (e.g. ~8AM and ~8PM every day).  At each dose administration, 5 
capsules of blinded study drug (equivalent to 125 mg of LAM-002A or placebo) should be taken. If a subject requires a dose modification for drug-related toxicity, 4 capsules of 
blinded study drug (equivalent to 100 mg of LAM-002A or placebo) should be taken. At each dose administration, all capsules sho uld be swallowed whole with 100 to 200 mL (~4 
to 8 ounces) of water. Subjects who have a delay in administration of <6 hours should take the planned dose as soon as possible after the intended time of administration. For 
subjects who have a delay in admini stration of ≥6 hours, the dose should not be taken. The planned timing of subsequent drug administration should not be altere d. For subjects 
who vomit shortly after taking the study drugs, the vomited dose should not be replaced. The planned timing of subs equent drug administration should not be altered.  
q. Empty, partially used, or full bottles of blinded study drug ( LAM -002A  or placebo) will be retrieved from the subject and drug compliance will be assessed throughout the dosing 
period. In addition, the sub ject’s dosing diary will be reviewed, any incomplete or inconsistent entries will be addressed, and the dosing diary will be photocopied.  
r. COVID -19 symptoms will be documented by the patient on the applicable diary every day and reviewed by the study staff on Day 1, Day  4, Day 6, Day 8, Day 11,  Day 22, Day 
28. Patients should be instructed to collect this data on their patient diary every day, at the same time they take their study drug, until study completion. Patients should be 
instructed to return the paper diary to each clinic visit for review by study personnel. A copy of the paper diary will be collected as part of the source documentati on and the 
original returned to the subject until the next visit. The original diary will be collected at the day 28 visit. Sites should schedule all visits, including phone visits, as close as possible 
to the drug dosing time on Day 1 to ensure consistenc y when reviewing patient symptoms.  
s. Serum or urine pregnancy testing will be performed in women of childbearing potential only. Pregnancy testing should be perfo rmed at Screening.  
t. Blood for genomic DNA and RNA will be used to assess for polymorphisms in the patient and the virus that may affect safety or efficacy; to be collected at Screening.  
u. Nasopharyngeal swabs collection to determine SARS -CoV -2 viral load and possibly sequence, expression biomarkers of target engagement and infectiou s disease diagnostic  
(Biofire or equivalent) to be collected on Day 1 (immediately prior to the first dose) and then on Day 4. The Day 4 swab should be obtained as close to 72 hours ( ± 4 hours) after 
the Day 1 dose as possible.  
v. Saliva collection to dete rmine SARS -CoV-2 viral load, and possibly sequence and expression biomarkers of target engagement  to be collected on Day 1 (immediately prior to the 
first dose) and then on Day 4, Day 11, and Day 28.  NOTE: The Day 4 sample should be obtained as close to 7 2 hours ( ± 4 hours) after the Day 1 dose as possible . 
w. Hematology to include hemoglobin, hematocrit, erythrocyte count, absolute counts of leukocytes, neutrophils, lymphocytes, mon ocytes, eosinophils, basophils; platelet count.  
Hematology testing should be performed on Day 1 (predose), and Day 11.  NOTE: Hematology results obtained within 30 days prior to the Screening visit are acceptable for the 
Day 1 sampling requirement.  
x. Serum chemistry to include sodium, potassium, chloride, bicarbonate, BUN,  creatinine, glucose, calcium phosphorus, magnesium, total protein, albumin, ALT/SGPT, AST/SGOT, 
ALP, CK, LDH, total bilirubin, uric acid to be collected on Day 1 (predose ) and Day 11. NOTE: Serum chemistry results obtained within 30 days prior to the Screening visit are 
acceptable for the Day 1 requirement.   
y. Blood to be split for plasma samples for cytokine analysis and cell pellet/PBMC for target engagement will be collected on Da y 1 (predose), Day 4 and Day 11. PBMC collection 
is optional.  
z. Only a few sites will collect pharmacokinetic data. Blood for LAM -002A pharmacokinetics will be collected predose on Day 1 and at 1 hr. (± 15 min.) and 2 hr.(± 15 min.) 
postdose, and on Day 11 (12 hours post the last dose on Day 10) to be performed in a subset of subjects as defined in the laboratory manual. Patients participating in 
pharmacokinetics will take study drug on Day 1 while fasting (defined as no food with the exception of clear liquids for ≥2  hours before and ≥1  hour after dosing).  
aa. Documentation of whether the subject has died or become hospitalized due to COVID -19 disease; documentation of whether the subject is symptom -free on Day 28.  
 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 21 of 91  Version 4 (16 October  2020)  2. INTRODUCTION  
In December 2019, the Wuhan Municipal Health Committee identified an outbreak of viral 
pneumonia cases of unknown cause. Coronavirus RNA was quickly identified in some of these 
subjects. This novel coronavirus has been designated SARS -CoV-2, and the disease caused by 
this virus has been designated COVID-19. Following exposure to SARS -CoV-2, a window of 
treatment opportunity to prevent progression of disease exists. After exposure, there is a ~5 -day 
incubation period (range 1-14 days), after which most individuals (~80%) develop mild disease. However, in high- risk individuals, including those ≥65 years of age, or those with pre -existing 
medical conditions  (e.g. chronic lung disease , heart disease, or vascular disease) , there is 
significantly increased risk of development of severe COVID-19 requiring intensive supportive care and often resulting in death.  
No vaccine prophylaxis exists for COVID-19 and only one antiviral agent, remdesivir, has been 
approved under emergency-use provisions for therapy of COVID-19.  Remdesivir has modest 
activity and must be given intravenously (IV), thus limiting its  utility for outpatient care of 
subjects with mild COVID-19 symptoms. Development of a well-tolerated, easy -to-administer 
oral therapy for treatment of subjects with COVID-19 could prevent disease progression  and 
consequent morbidity, need for intensive care, and mortality.  
2.1. Study Rationale  
The enzyme phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) is known to be responsible for 
viral entry into cells. LAM -002A is a clinically tested, orally bioavailable, specific PIKfyve 
kinase inhibitor with in vitro  antiviral activity against Ebola (EBV), Marburg  (MARV), and the 
coronaviruses MERS -CoV, SARS -CoV, and SARS -CoV-2 ( Ou et. al, 2020, Nelson et al, 2017 ; 
Qiu et al 2018; Riva et al., 2020; Kang et al, 2020).  
AI Therapeutics plans to conduct a Phase II randomized, double-blind, placebo-controlled, study 
of LAM -002A to test if LAM -002A can  prevent the progression of COVID-19 in subjects with 
mild COVID-19.  
The study will enroll men and women within 8 days of symptom onset, who are ≥ 18 years of 
age, have documented SARS -CoV-2 infection as confirmed by a positive validated test , and have 
mild disease appropriate for initial outpatient care . 
The appropriate dose and safety of LAM -002A administration has been established through data 
from several  clinical studies  that enrolled more than 700 combined healthy subjects and subjects 
with inflammatory and malignant conditions (see LAM -002A IB V5 ). A d ose-range -finding 
study of LAM -002A in subjects with hematological cancers indicated that LAM -002A was not 
well tolerated at doses of 150 mg BID due to the rapid onset of nausea, vomiting, and/or diarrhea 
that preclude compliance with therapy. However, when administered at 125 mg  BID, the drug 
demonstrated anticancer efficacy , and  was well tolerated with excellent compliance , over a 
period of 2 years. Toxicities at this dose level were  infrequent nausea, vomiting, and/or diarrhea, 
requiring dose reduction to 100 mg BID in <10% of subjects. Accordingly, this same dosing regimen  is proposed for evaluation in this study in subjects with COVID-19. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 22 of 91  Version 4 (16 October  2020)  2.2. Background 
2.2.1. LAM -002A Mechanism of Action  
Viral entry into cells ha s been shown to occur through components of the endosomal network, 
including Rab9 GTPase, the endo/lysosomal cholesterol transporter Niemann- Pick C1 (NPC1) 
(Murray et.al; 2005; Carette et. al., 2011), and phosphatidylinositol-3-phosphate 5- kinase 
(PIKfyve) ( Murray et.al; 2005; Carette et. al., 2011; Nelson  et.al., 2017 ; Qiu et.al., 2018).   
PIKfyve, is a 240- kDa endosomal phosphatidylinositol (PI) 5 lipid kinase that catalyzes the 
phosphorylation of phosphatidylinositol 3-phosphate (PI(3)P) to phosphatidylinositol 3,5-
bisphosphate (PI(3,5)P 2). PIKfyve regulates endosome and lysosome biogenesis and intracellular 
trafficking, facilitating late -endosome- to-trans -Golgi vesicular transport. This vesicular transport 
is part of the endosomal network that viruses use to enter the cell and replicate, suggesting PIKfyve inhibition can inhibit viral entry into cells and decrease viral replication.  
LAM -002A is a first- in-class inhibitor of PIKfyve with an IC
50 of 14nM, and K d of 
approximately 75 pM (range 69-81 pM). The potential of LAM -002A to inhibit coronavirus viral 
entry has been tested in vitro . Apilimod potently blocked the entry of severe acute respiratory 
syndrome (SARS)  and Middle East respiratory syndrome (MERS) pseudotyped virus at all 
concentrations tested (62.5 -250 nM) which  has been independently replicated by Ou  et.al., 2020. 
Importantly apilimod also blocked  the entry of lentiviral pseudovirions expressing the 
SARS -CoV-2 S glycoprotein and displayed  activity against several independent clinical isolates 
of SARS -CoV-2 ( Ou et. al., 2020; Riva  et al, 2020; Kang  et al,  2020) . Furthermore, 
combinatorial activity was observed with remdesivir suggesting that greater antiviral efficacy may be achieved with apilimod in combination with other anti -viral agents. T aken together, the 
effect on endolysosomal trafficking and in vitro anti -viral activity  indicate that LAM -002A, the 
dimesylate salt of apilimod, has promising therapeutic potential for treating SARS -CoV-2 
infections .  
LAM -002A has also been found to potently inhibit the production of T-helper lymphocyte type 1 
(Th1) cytokines IL-12 and IL- 23 in PBMCs when treated with multiple toll- like receptor (TLR) 
stimuli (LAM -002A IB V4 ). In addition, LAM -002A inhibits IL -6 in response to IFN -γ/SAC 
(Wada et.al,  2007). Significant reduction of IL -12 and IL-23 transcripts, with a simultaneous 
increase in IL -10 was also observed in the skin lesions of psoriatic subjects treated with apilimod 
at 70 mg of apilimod free base QD ( Wada et.al , 2012). While the stimuli and role of specific 
cytokines in COVID-19 are not known, these data suggest that LAM -002A has the potential to  
repress pro-inflammatory cytokines (e.g. IL- 12, IL -23) and induc e anti -inflammatory cytokines 
(e.g. IL- 10). 
2.2.2. Human Experience with LAM -002A 
In addition to its anti- viral mechanism of action, the study rationale for LAM -002A in subjects 
infected with SARS -CoV-2 is based on the well -established safety and tolerability profile of the 
molecule in human trials .  
 Safety and Tolerability  
LAM -002A has a well -established clinical record supporting its safety and tolerability, including 
published literature (LAM -002A IB V5). Under IND 125,763, AI Therapeutics sponsored a 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 23 of 91  Version 4 (16 October  2020)  Phase 1 dose-ranging and expansion study evaluating the safety, pharmacokinetics, 
pharmacodynamics, and anticancer activity of LAM -002A in subjects with recurrent, previously 
treated non- Hodgkin lymphoma ( NHL ). Study results indicate that LAM -002A is very well 
tolerated and has a favorable safety profile at doses of ≤ 125 mg BID (250 mg total daily dose) . 
To date, >700 study subjects have received apilimod dimesylate or apilimod,  including 186 
healthy subjects participating in clinical pharmacology studies, 468 subjects with nonmalignant 
inflammatory conditions (psoriasis, rheumatoid arthritis, Crohn’s disease) , and 62 subjects with 
B-cell hematological cancers.  
Most observed adverse events or laboratory abnormalities have been low- grade, infrequent, and 
largely attributable to the underlying disease, prior therapy, concomitant medications, or other conditions. Continuous oral administration of LAM -002A has been w ell tolerated in humans 
with dosing regimens of ≤125 mg BID (≤250 mg total daily dose). In subjects with cancer, dosing regimens of 150 mg BID (300 mg QD) or 75 mg TID (225 mg QD) were not well tolerated due to symptoms of nausea, vomiting, and diarrhea that effectively precluded drug 
compliance in most subjects.  
 LAM -002A Pharmacokinetics in Humans  
The pharmacokinetics of LAM -002A was  studied in healthy subjects and in subjects with 
hematological cancers as a monotherapy and in combination with rituximab, or atezolizumab. LAM -002A (apilimod free base of LAM -002A) was rapidly bioavailable following oral dosing 
with an approximate T
max of 1 hour. The C max and AUC 0-8 generally increased with increasing 
dose; the Day 8 AUC 0-8 showed the closest relationship to dose proportionality. As steady- state 
exposures were achieved, mean Day 8/Day 1 accumulation indices (AI) for C max and AUC 0-8 
across all dose levels were 1.3 and 1.7, respectively. Mean terminal t 1/2 values ranged from 2.7 to 
3.9 hours on Day 1 and from 5.4 to 7.0 hours on Day 8 and did not show dose dependency. On the first day of administration, ~90% of the drug was cleared within 10 hours after which the 
remaining drug was eliminated with a termina l t
1/2 of 5 to 10 hours. The terminal t ½ increased to 
12 to 21 hours on Day 14 in healthy subjects. 
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected adverse events of  LAM -002A may be found in the LAM -002A IB V5 . 
There have been no subjects with COVID-19 or SARS -CoV -2 exposures evaluated to date, and 
the risk/benefit of LAM -002A in COVID-19 is not understood. The safety and tolerability of 
LAM -002A has been established, with >800 subjects treated with the drug as of March 20, 2020. 
Overall, product administrations were well tolerated. Gastrointestinal TEAEs of nausea, 
vomiting, and diarrhea were commonly observed, and showed dose dependency, with most 
TEAEs being of Grade 1 or 2. At 125 mg BID, LAM -002A was found to be safe and tolerable. 
No vaccine prophylaxis exists for SARS -CoV-2 infection and only one antiviral agent, 
remdesivir, has been approved under an emergency -use authorization for therapy for COVID-19.  
Remdesivir has modest activity and must be given intravenously (IV), thus limiting its utility for outpatient care of subjects with mild COVID-19 symptoms. While anti -viral efficacy of 
LAM -002A has not been established in humans or in animal models, the in vitro anti-vi ral 
activity suggests it may have potential efficacy in humans. Development of a well -tolerated, 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 24 of 91  Version 4 (16 October  2020)  easy-to-administer oral therapy for treatment of subjects with COVID-19 could prevent disease 
progression and consequent morbidity, the need for intensive care, and mortality.  
A planned interim analysis with DSMB review early in the trial after 15 subjects in each 
treatment arm have completed treatment ensures the mitigation of any unanticipated safety risk in this COVID-19 population.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 25 of 91  Version 4 (16 October  2020)  3. STUDY OBJECTIVES  
3.1. Primary Objective  
 To evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 with a baseline 
viral load >105 copies/mL as measured by SARS -CoV-2 clearance as determined by a 
qRT-PCR test  from nasopharyngeal samples at Day 4  (72 hours ± 4 hours post the first drug 
dose) 
3.2. Secondary Objectives  
• To evaluate the safety and tolerability of LAM- 002A administration in the treatment of 
subjects with mild COVID -19. 
• To evaluate the efficacy of LAM -002A in preventing COVID-19 disease progression in 
subjects who have proven infection with the SARS -CoV-2 virus as determined by a validated  
test; disease progression is defined as the occurrence of any of the following:  
o Death at Day 28 
o Hospitalization at Day 28 
• To evaluate change in COVID-19 clinical status , as defined by the ordinal scale, of subjects 
treated with LAM -002A compared to placebo at Day 28, in subjects who become 
hospitalized and continue LAM -002A /placebo treatment.  
• To compare the proportion of subjects at or above 95% oxygen saturation (O 2 sat) between 
LAM -002A versus placebo treatment  groups as measured on Days 1, 4, and 11.  
3.2.1. Safety and Tolerability  
 To evaluate the safety and tolerability of LAM -002A administration in the treatment of 
subjects with COVID- 19. 
3.2.2. Clinical Efficacy  
 To evaluate the efficacy  of LAM -002A in preventing COVID-19 progression in subjects who 
have proven infection with the SARS -CoV-2 virus as determined by a validated  test; disease 
progression is defined as the occurrence of any of the following: 
o Death at Day  28 
o Hospitalization  at Day  28 
3.2.3. Clinical Status  
 To evaluate change in COVID-19 clinical status as defined by the ordinal scale of  subjects 
treated with LAM -002A compared to placebo  at Day 28, in cluding the subjects who become 
hospitalized and continue LAM -002A /placebo treatment.   
3.2.4. Oxygen Saturation 
 To compare the proportion of subjects at or above 95% oxygen saturation (O2 sat) between 
LAM -002A versus placebo treatment  groups as measured on Days 1, 4 and 11.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 26 of 91  Version 4 (16 October  2020)  3.3. Exploratory Objectives  
3.3.1. Pharmacokinetic  
 To potentially evaluate the pharmacokinetics of LAM -002A in subjects with mild 
COVID-19. 
3.3.2. Viral Clearance 
 To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 with 
a baseline viral load >105 copies/mL as measured by SARS -CoV-2 clearance as determined 
by a qRT -PCR test  from saliva samples at Day 4. 
 To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 with 
a baseline viral load >105 copies/mL as measured by SARS -CoV-2 clearance as determined 
by a qRT -PCR test  from saliva samples at Day 11. 
 To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 with 
a baseline viral load >105 copies/mL  as measured by SARS -CoV-2 clearance as determined 
by a qRT -PCR test  from saliva samples  at Day 2 8.  
 To potentially evaluate the antiviral efficacy of LAM -002A in subjects with COVID-19 with 
a baseline viral load >105 copies/mL as measured by SARS -CoV- 2 clearance as deter mined 
by a qRT -PCR from saliva samples at all available days based on AUC analysis. 
 To potentially evaluate the difference in proportion of subjects with a SARS -CoV- 2 viral 
load <LLOQ  between the LAM-002A and the placebo arm as measured by a qRT -PCR test 
from nasopharyngeal samples at Day 4. 
3.3.3. Pharmacodynamic Objective s 
 To potentially evaluate the effect of LAM -002A on target engagement biomarkers. 
 To potentially evaluate the effect of LAM -002A on pro- and anti -inflammatory cytokine 
levels in plasma of COVID-19 subjects. 
3.3.4. Genetic Evaluation Objectives  
 To potentially evaluate viral resistance by comparing genomic sequence of SARS -CoV -2 
before and after LAM -002A treatment. 
 To potentially evaluate the effect of SARS -CoV-2 genetic variants on LAM -002A efficacy . 
 To potentially evaluate the effect of germline DNA sequence polymorphisms on LAM -002A 
safety and efficacy . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 27 of 91  Version 4 (16 October  2020)  4. STUDY ENDPOINTS  
4.1. Primary Endpoint  
 The primary efficacy outcome measure evaluates change in SARS -CoV-2 viral load at Day 4 
from Day 1, of LAM-002A or placebo- treated subjects. SARS -CoV-2 viral load will be 
measured by a qRT -PCR test of nasopharyngeal samples. Analysis will focus on log 10 viral 
load on Day 4 compared to baseline viral load at Day 1 in subjects with baseline viral load 
>105 copies/mL. 
4.2. Secondary Endpoints  
4.2.1. Safety and Tolerability  
 The proportion of LAM -002A-treated subjects who develop TEAEs compared to placebo. 
4.2.2. Clinical Efficacy  
 The proportion of subjects treated with LAM -002A compared to placebo, who have disease 
progression by Day  28 as defined by the occurrence of:  
o Hospitalization  
o Death  
4.2.3. Clinical Status  
• Change in COVID-19 clinical status as defined by the ordinal scale, of subjects treated with LAM -002A compared to placebo  at Day 2 8, in subjects who become hospitalized and 
continue LAM -002A/placebo treatment, based on the following scores: 
1. Not in the hospital 
2. Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula)  
3. Hospitalized, not on invasive ventilation (such as 100% non- rebreather, BIPAP), (pre -
ICU) 
4. Hospitalized, in the ICU, on invasive ventilation or ECMO 
5. Dead  
4.2.4. Oxygen Saturation 
• Proportion of subjects at or above 95% oxygen saturation (O2 sat) between LAM -002A 
versus placebo as measured on Day s 1, 4, and 11. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 28 of 91  Version 4 (16 October  2020)  4.3. Exploratory Endpoints  
4.3.1. Pharmacokinetics  
 Plasma concentration time profile of LAM -002A, on Day 1 pre-dose, at 1 (± 15 min) and 
2 (± 15 min.) hr, and at trough on Day 11 will potentially be determined in a subset of 
subjects (target 20 subjects) to evaluate the deviation of pharmacokinetic parameters from 
expected exposure, and correlation of pharmacokinetic parameters with safety and e fficacy . 
 Maximum observed concentrations within the bounds of the sampling time points and trough 
concentration on Day  11. 
4.3.2. Viral Clearance 
 Change from baseline (Day 1, Pre-dose) of SARS -CoV-2 viral load as measured by a 
qRT-PCR test from saliva samples on Day 4 , compared between the LAM -002A arm and the 
placebo arm in subjects with a baseline viral load >105 copies/mL . 
 Change from baseline (Day 1, Pre-dose) of SARS -CoV-2 viral load as measured by a 
qRT-PCR test  from saliva samples on Day  11, compared between the LAM -002A arm and 
the placebo arm  in subjects with a baseline viral load >105 copies/mL . 
 Change from baseline (Day 1, Pre-dose) of SARS -CoV-2 viral load as measured by a 
qRT-PCR test  from saliva samples on  Day  28, compared between the LAM -002A arm and 
the placebo arm  in subjects with a baseline viral load >105 copies/mL . 
 Difference in SARS -CoV-2 viral load as measured by a qRT -PCR test  from saliva samples 
based on AUC( Day1-Day 11), between the LAM -002A arm and the placebo arm  in subjects with 
a baseline viral load >105 copies/mL . 
 Difference in SARS -CoV-2 viral load as measured by a qRT -PCR test  from saliva samples 
based on AUC( Day1-Day28 ), between the LAM -002A arm and the placebo arm  in subjects with 
a baseline viral load >105 copies/mL . 
 Difference in proportion of subjects with a SARS -CoV-2 viral load <LLOQ as measured by a 
qRT-PCR test  from nasopharyngeal samples between the LAM-002A and the placebo arm at 
Day 4. 
4.3.3. Pharmacodynamics 
• Changes in  the expression of target engagement biomarkers  in the nasal epithelium, PBMCs, 
and plasma. 
4.3.4. Immunogenicity  Endpoints  
• Changes in plasma levels of IL -12, IL -23, and IL-6, IFN -γ, IL-10 and GM- CSF (additional 
cytokines may be analyzed in parallel). 
4.3.5. Genetic Endpoints  
• Changes in viral genome sequence before and after LAM -002A treatment . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 29 of 91  Version 4 (16 October  2020)  • Effect of SARS -CoV-2 genetic variants on efficacy (% of subjects that progress per variant), 
as determined by viral genome sequencing.  
• Effect of genetic polymorphisms on LAM -002A safety and efficacy . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 30 of 91  Version 4 (16 October  2020)  5. STUDY DESIGN AND CONDUCT  
5.1. Study Design  
This is a double- blind, randomized, placebo -controlled Phase II study for the treatment of 
SARS -CoV-2 positive outpatient individuals with LAM -002A. The study will compare the 
active arm of LAM -002A plus standard of care, with the control placebo arm plus standard of 
care. This study will be conducted in approximately 142 adult subjects ages ≥ 18, with  < 8 days 
of symptom onset, who are SARS -CoV-2 positive as determined by a validated test.  The study 
will enroll subjects who have at least one of the following COVID-19- related symptoms 
indicating mild disease: fever (temperature ≥100.4), anosmia (loss of taste or smell), cough, sore 
throat, gastrointestinal complaints (e.g. nausea, vomiting or diarrhea), chills, congestion or runny 
nose, headaches, muscle or body aches, fatigue, without shortness of breath or dyspnea (RR<20, SpO2 >93% on room air), or  asymptomatic patients who have tested positive for COVID-19 via 
a validated  test within the past 4 days.  Subjects will be  treated  with 125 mg LAM -002A PO, 
BID, or with placebo PO, BID for 10 days (20 doses). The treatment schedule is outlined in the 
Schedule of Activities (SoA), 
Table  1. Subjects will be followed at 4, 6, 8, 11, 22 and 28 days 
after the treatment start.  
Subjects will be randomized using a permuted block scheme (with variable block size) in a 1:1 ratio to one of the two groups: (1) LAM -002A, or (2) placebo. To assure at least 71 placebo 
participants  have a viral load ≥2 ×10
3 copies/mL (the lower limit of detection of the assay) at 
Day 4, 142 participants with baseline viral load >105 copies/mL will be enrolled to achieve the 
primary objective; thus, an expected 142 subjects will be randomized (71 to receive LAM -002A 
and 71 to receive placebo). Because the existing longitudinal data on viral load in subjects are 
preliminary, this baseline viral load and number of participants  randomized may be adjusted to 
allow for 71 placebo participants above the lower limit of detection o f the assay (≥  2 × 103 
copies/mL) at Day 4 so that a difference in viral clearance between the groups can be assessed.   
5.2. Study Conduct  
The study will be performed in accordance with the principles as set forth under the requirements of 21 Code of Federal Regulations (CFR) 50 and the ICH E6 GCP guideline. The research will 
be overseen by an institutional review board/independent ethics committee (IRB/IEC). The study 
protocol, any protocol amendments, informed consent documents, and any material used to descri be the trial to potential subjects will be reviewed and approved by the IRB/IEC prior to the 
performance of any study- related procedures.  
AI Therapeutics, Inc. will serve as the regulatory sponsor for the study and will maintain an investigational new drug (IND) application with the FDA. The protocol will be submitted to an 
IND for LAM -002A (IND#1 48521) and the trial design and results will be subject to review by 
the FDA.  
A designated clinical  research organization (CRO) will serve as the operational coordinator of 
the study and will oversee conduct of the study at participating study centers.  The CRO will 
perform activities relating to pharmacovigilance; site monitoring; data management and study 
reporting; and sample handlin g. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 31 of 91  Version 4 (16 October  2020)  The study will employ an independent Data Safety Monitoring Board (DSMB) for safety and 
clinical efficacy and analysis of viral clearance efficacy data. AEs and serious adverse events 
(SAEs) will be reviewed by the DSMB on an ongoing basis to identify any safety concerns. Conference calls among the members of the DSMB will be conducted periodically to discuss study progress, exchange study information, and review safety events (in particular, DLTs; 
SAEs; adverse events of special interest; and A Es leading to dose interruption, dose reduction, or 
therapy discontinuation), and discuss potential amendments to the protocol. 
The DSMB will be responsible for  reviewing the  interim safety and efficacy analyses and 
recommend ing study continuation, termination, or adaptation. A n interim safety analysis of study 
data will be performed after the first 30 subjects (15 on LAM -002A and 15 on placebo) have 
completed treatment and have been followed up for 11 days post- first dose.  During the analysis, 
study enrollment will not be halted. Recommendations from the DSMB  will be used for decision 
of early termination , continuation, or study design adaptations.  
5.3. Rationale for Study Design 
The study is a randomized, placebo controlled, multi-center study in approximately 142 adults 
ages ≥1 8, randomized to LAM -002A or placebo in a 1:1 ratio. The study has been designed to 
provide data on the efficacy , safety , pharmacokinetics, and pharmacodynamics of LAM -002A in 
subjects with mild COVID-19 symptoms. After exposure with SARS -CoV-2, there is 
approximately a 5-day incubation period (range 1-14 days) ( Guan et. Al., 2020; Li et.al., 2020; 
Lauer et. A l., 2020), after which most individuals (~ 80%) develop a mild disease. The study has 
been designed to treat  individuals with antiviral LAM -002A early in the infection period, to 
reduce the viral load  of SARS -CoV-2 and prevent COVID-19 progression.  
In order to mitigate unanticipated safety issues in this COVID-19 population, an  early interim 
safety analysis after 30 subjects (15 on LAM -002A and 15 on placebo) have been treated and 
followed for 11 days, will be performed , and reviewed by a DSMB for decision on study 
continuation, termination or study adaptation.  
The primary outcome measure is reduction in SARS -CoV-2 viral load measured in 
nasopharyngeal samples at Day 4  in LAM -002A treated subjects compared to those on placebo. 
Explorato ry outcome measures of SARS -CoV-2 viral load from saliva samples  at Days 1, 4, 11, 
and 28 are included to further inform on the rate of viral clearance. For the primary and 
secondary objectives examining antiviral efficacy, the analysis will focus on the subgroup of 
randomized subjects with baseline viral load > 10
5 copies/mL. This subgroup was chosen 
because subjects in this group are predicted to have sufficient viral load at baseline for the study 
drug to show benefit when compared to placebo. Because the existing longitudinal data on viral 
load in participants are preliminary, this baseline viral load and number of participants  
randomized may be adjusted to allow for 71 placebo participants above the lower limit of 
detection of the assay (≥ 2228 copies/mL; see S ection 10.1) at Day 4 such that a difference in 
viral clearance between the groups can be adequately assessed. Nasopharyngeal swabs to 
evaluate baseline viral load will be performed prior to randomization; however, results on viral 
load will not be available prior to initiation of treatment. Supportive analyses for viral load 
outcomes will be performed in all randomized participants.  
Secondary outcome measures of hospitalization  or death at Day 28, and clinical status  
determination using the Ordinal Scale will further inform on efficacy of the drug  and provide 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 32 of 91  Version 4 (16 October  2020)  valuable information for Phase III trials . In addition, safety and tolerability  analyses are planned 
as secondary outcome measures . Exploratory pharmacokinetic and pharmacodynamic outcome 
measures of target engagement  and biomarkers (pro- and anti- inflammatory cytokine analysis) 
have been included to inform on the mechanism of action. Additional viral clearance measures, 
as determined from SARS -CoV- 2 viral load in saliva samples are included as exploratory 
endpoints.  Additional exploratory outcome measures are designed to explore resistance of 
SARS -CoV-2 genome variants to treatment with LAM -002A and how the subject’ s germline 
DNA may impact safety or efficacy of LAM -002A in this disease.   
5.4. Justification for Dose  
The dose of 125 mg BID LAM -002A (apilimod dimesylate) chosen for the COVID- 19 trial is 
based on safety, exposure and efficacy data from a clinical trial in patients with B -cell 
lymphomas and from in vitro measurements of potency in SARS -CoV-2 viral infection assays.  
The recommended dose of 125 mg BID was established in a Phase 1 population of 62 patients with previously treated, advanced, B-cell lymphomas. The study population median (range) of ages was 69 (46 -89) years and patients were equally divided among males (n=32) and females 
(n=30). Patients typically had cancer- related sy mptoms and often had additional comorbidities 
(eg, diabetes mellitus, chronic obstructive lung disease, cardiovascular disease). Thus, the population evaluated was highly relevant to the population to be studied in the LAM -002A 
COVID-19 trial.  
Among these 62 patients, 39 received the recommended LAM -002A oral, continuous dosing 
regimen of 125 mg BID, either alone or in combination with the anti -CD20 antibody, rituximab, 
or the anti -PD-L1 antibody, atezolizumab (neither of which had overlapping toxicities with 
LAM -002A). Durations of therapy extended to >600 days and therapy is still ongoing in several 
patients. Of importance, the  only  evident drug- related adverse events (AEs) observed with this 
LAM -002A dosing regimen were gastrointestinal in nature. When th ey occurred, such events 
were seen in  a minority of patients, were typically low -grade, and were readily managed with 
dose modification. Over the entire course of chronic treatment lasting many months, incidences 
of Grade 1- 4 gastrointestinal AEs of any cause were nausea in 14/39 (35.9%) patients, vomiting 
in 10/39 (25.6%) patients, and/or diarrhea in 10/39 (25.6%) patients. The incidences of Grade 3-
4 gastrointestinal AEs of any cause were low: nausea in 2/39 (5.1%), vomiting in 1/39 (2.6%), 
and diarrhea in 0/39 (0%); in these patients, other reasons for such events were documented (eg, 
central nervous system tumor, gastrointestinal lymphoma, or viral gastroenteritis). As a consequence of this excellent safety profile, median compliance with therapy was >97 % in the 
39 subjects. Symptoms leading to LAM -002A dose modification were primarily nausea or 
diarrhea and appeared to be LAM -002A- related in 4  (10.2%) subjects; gastrointestinal symptoms 
in these subjects lessened or resolve upon dose reduction and LAM -002A could be continued. It 
should be further emphasized that LAM -002A did not cause any disabling or life-threatening 
toxicities and did not cause cardiac or respiratory events that might worsen symptoms of COVID-19 or confound interpretation of COVID -19 manifestations.  
Furthermore, clinical efficacy was observed in patients with follicular lymphoma at the recommended dose of 125 mg BID. Among the 17 patients with follicular lymphoma , 9 with 
follicular lymphoma were treated with LAM -002A monotherapy or LAM -002A-based 
combination therapy at this dose level and had substantial tumor regressions meeting established 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 33 of 91  Version 4 (16 October  2020)  criteria for objective response [ Cheson  2014]. Objective responses have been long-lasting, with 
durations exceeding 12 months among several subjects and are ongoing in 3 subjects who are 
still on therapy. When taken together with the safety and exposure data, these efficacy findings 
document that a dministration 125 mg BID of LAM -002A is pharmacologically active in 
producing a desired clinical effect with a well -tolerated dosing regimen.  
LAM -002 ( apilimod), the active form of LAM -002A, has potent nanomolar in vitro activity 
against several independe nt clinical isolates of SARS -CoV-2 in Vero E6 cells [ Riva  2020 ; 
Kang  2020]. Based on these data ( Table 2), the EC 50 is between 10 and 23 nM and the EC 90 is 
estimated to be between 10 and 400 nM in Vero E6 cells.  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 34 of 91  Version 4 (16 October  2020)   
Table 2. Summary of LAM -002A In Vitro Activity Agains t SARS CoV -2 
Reference  SARS -CoV-2 Isolate Cell Line  EC 50 EC 90 
AI Therapeutics  Hangzhou, China  Vero E6  <1.25 µM <1.25 µM 
Riva 2020  USA-WA1/2020  Vero E6  23 nM  >100 nM to <400 nM  
Kang  2020  USA-WA1/2020  Vero E6  10 nM  >10 nM to <50 nM  
These LAM -002 concentrations are similar to those active against B- cell non -Hodgkin 
lymphoma cell lines in vitro [ Gayle  2017a ]. Given the clinical responses observed in B- cell 
lymphoma patients at 125 mg BID and evidence of target inhibition in patient plasma samples, it 
would therefore be predicted that this dose would also provide efficacious drug levels in 
COVID-19 patients. Ind eed, at 125 mg BID the plasma concentrations of active drug, which 
includes LAM -002 and its active metabolites (STA -5908, STA -5944, and STA-6048) weighted 
by their relative cell based activity and exposure, exceed the average in vitro anti- viral EC 90 
(205 nM) in Vero E6 cells by 1.5 times at trough and by 7.4 times at C max. Furthermore, a rat 
distribution study of oral administration  of [14C]-apilimod suggests that lung exposures are 1.1 to 
1.5 times higher than in blood, providing further rationale that 125 mg BID would provide sufficient drug levels for anti- viral activity in lung tissues.  
Consequently, it is the AI Therapeutics position that the LAM -002A dosing regimen of 
125 mg  BID maximizes the potential for antiviral benefit in patients with COVID-19 and will be 
safe and well tolerated over the planned treatment course.   
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 35 of 91  Version 4 (16 October  2020)  6. STUDY POPULATION  
This clinical trial can fulfill its objectives only if appropriate participants are enrolled. The 
protocol- specified eligibility criteria are designed to select subjects for whom study participation 
is considered appropriate. All relevant medical and non-medical conditions should be taken into consideration when deciding whether this protocol is suitable for a study candidate. Eligibility criteria may not be waived by the investigator and conformance to the eligibility criteria will be reviewed in the case of a GCP or a regulatory authority audit. Any questions regarding a study 
candidate’s eligibility should be discussed with the medical monitor before enrollment. Reference is made to the National Early Warning Score (NEWS) for grading of illness intensity and the Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0 for severity of adverse events. 
6.1. Inclusion Criteria  
Study candidates must meet all of the following inclusion criteria to be eligible for participation 
in this study:  
1. Men and women of age ≥18 years.  
2. Written documentation of SARS -CoV-2 infection confirmed by a validated test . 
3. Presence of ≥1 of the following COVID 19- related symptoms indicating mild disease: fever 
(temperature ≥100.4), anosmia (loss of taste or smell), cough, sore throat, gastrointestinal complaints (e.g. nausea, vomiting or diarrhea), chills, congestion or runny nose, headaches, muscle or body aches, fatigue , or asym ptomatic patients who have tested positive for 
COVID-19 via a validated test within the past 4 days.  
4. If symptomatic, symptom onset ≤8 days. 
5. For female subjects of childbearing potential, a negative urine (or serum) pregnancy test.  
6. For female subjects of childbearing potential, willingness to use a protocol- recommended 
method of contraception from the start of the screening period until ≥30 days after the final dose of study therapy. Note: A female subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle- stimulating hormone 
[FSH] levels within the institutional laboratory postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βHCG]); or is menopausal (age ≥50 years 
with amenorrhea for ≥6 months).  
7. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥30 days after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. Note: A male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy. 
8. Willingness and ability of the subject to ingest study drug capsules. 
9. Willingness of the subject to comply with scheduled visits, drug a dministration plan, 
protocol-specified laboratory tests, study procedures, and study restrictions.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 36 of 91  Version 4 (16 October  2020)  10. Evidence of a personally signed informed consent indicating that the subject is aware of the 
nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation. 
6.2. Exclusion Criteria  
Study candidates who meet any of the following criteria will not be eligible for participation in this study: 
1. Respiratory rate ≥20 breaths per minute.  
2. Oxygen saturation by pulse oximetry ≤93% on room air or requirement for supplemental 
oxygen to maintain oxygen saturation >93%. 
3. Total NEWS score ≥6 or presence o f a score of 3 on any of the individual NEWS parameters. 
4. Radiographic evidence of pulmonary infiltrates (clinical X -ray within 2 days of referral)  
5. Hepatic profile showing any of the following: 
• Serum alanine aminotransferase (ALT) >5 × upper limit of normal  (ULN) (CTCAE 
Grade ≥3).  
• Serum aspartate aminotransferase (AST) >5 × ULN (CTCAE Grade ≥3).  
• Serum bilirubin >1.5 × ULN (CTCAE Grade ≥2). 
6. Renal profile showing an estimated creatinine clearance (eClCR) <30  mL/minute (with 
eClCR to be calculated by the metho d at the laboratory performing the serum creatinine test).  
7. Presence of a cancer with disease manifestations or therapy that could adversely affect 
subject safety or longevity, create the potential for drug- drug interactions, or compromise the 
interpretatio n of study results. 
8. Significant cardiovascular disease (e.g. myocardial infarction, arterial thromboembolism, cerebrovascular thromboembolism) within 1  month prior to start of study therapy; unstable 
angina; symptomatic peripheral vascular disease;  CTCAE Grade ≥2 congestive heart failure; 
or uncontrolled CTCAE Grade ≥3 hypertension (diastolic blood pressure ≥100 mmHg or systolic blood pressure ≥160 mmHg) despite antihypertensive therapy.  
9. Significant screening ECG abnormalities, including atrial fibrillation/flutter, 2
nd degree 
atrioventricular (AV) block type II, 3rd -degree AV block, Grade ≥2 bradycardia, or corrected 
QT (QTc by Fridericia [QTcF]) >480 msec (Grade >1).  
10. Gastrointestinal disease (e.g. gastric or intestinal bypass surgery, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.  
11. Pregnancy or breastfeeding. 
12. Prior solid organ transplantation. 
13. Use within 5 days prior to randomization of an approved or investigational therapy intended to treat COVID-19 (e.g. remdesivir, anti- interleukin [IL] -6 antibodies, therapeutic anti-
SARS -COV -2 antibodies or post- convalescent plasma, anti- SARS -COV -2 vaccine, Bruton 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 37 of 91  Version 4 (16 October  2020)  tyrosine kinase [BTK] inhibitor), use within 3 months of chloroquine or hydroxychloroquine. 
Note: Subjects are not precluded from undergoing evaluations involving observation, noninvasive diagnostic procedures or sampling, or questionnaires as follow-up to a prior study or as components of a concurrent noninterventional study . 
14. Use within 5 days prior to randomization of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong inhibitor or inducer of CYP3A4 during study therapy (see Appendix 15.1 for a list of drugs known to be strong inhibitors or inducers of CYP3A4).  
15. Use within 5 days prior to randomization of drug that is a moderate -to-strong substrate of 
CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or expected requirement for chronic use of such drugs during study therapy.  
16. Use within 5 days prior to randomization of a drug known to prolong the QT interval (see Appendix 15.2 for a list of drugs that are considered to have a known propensity to prolong the QT interval).  
17. Ongoing immunosuppressive therapy including systemic or enteric corticosteroids. (Note: At study entry, subjects may be using intraarticular, inhaled, or topical corticosteroids. During 
study therapy, subjects may use systemic, enteric, intraarticular, inhaled, or topical corticosteroids as required for intercurrent conditions.) 
18. Any illness, medical condition, organ system dysfunction, or social situation, including mental illness or substance abuse, deemed by the investigator to be likely to interfere with a subject’s ability to provide informed consent, adversely affect the subject’s ability to cooperate and participate in the study, or compromise the inte rpretation of study results.  
 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 38 of 91  Version 4 (16 October  2020)  7. STUDY D RUG  ALLOCATION 
7.1. Randomization 
After a subject has completed the necessary screening assessments and has been confirmed to be 
eligible, the subject can be randomized into the study. In order to obtain a treatment arm assignment for a subject, a site representative will submit the appropriate information  for 
randomization, and the system will make an assignment of a study drug bottle number. Subjects will be randomized in a 1:1 ratio (Arm A:Arm B) to either of the following treatment assignments:  
• Arm A: LAM -002A 
• Arm B: Placebo  
In order to  balance treatment allocation, a permuted  block centralized randomization will 
allocate subjects.  
It is anticipated that subjects will usually begin study drug immediately after randomization Day 1 of the study. In case of administrative delays, every attempt should be made to initiate study drug treatment by Day 2. 
7.2. Blinding  
The identity of the treatments will be concealed by central blinding of study drug assignments. 
Blinding will be accomplished through use of a placebo that is well- matched to the active drug in 
appearance, packaging, labeling, and schedule of administration. During the study, subjects, caregivers, investigational site personnel, study sponsor  study team members, and all other study 
personnel will remain blinded to the identity of the  treatment assignments; these assignments 
will be available only to the unblinded randomization team, and the  DSMB for the study, an 
independent bioanalytical group, and drug safety personnel who are not part of the study team. Unblinding during the study will only occur in the case of subject emergencies (see Section  8.3) 
or as requested by the DSMB. Where required by local regulation, expedited reporting of serious adverse events to specific regulatory authorities will include information regarding the study drug treatment assignment (LAM -002A or placebo); this will be done in such a way that 
subjects, investigational site personnel, institutional review board/independent ethics committees (IRB/IEC), and study team members remain blinded as to the treatment assignment for the subject described in the adverse event report.  
The final unblinded analysis of the study will only be performed w hen the database is completed 
and locked. While bioanalytical assays to determine LAM -002A concentrations may be 
performed prior to unblinding, pharmacokinetic data that would allow identification of treatment assignments for individual subjects will not b e available to the study team until after the blind is 
broken and the primary analysis has occurred. Except for emergency unblinding, individual subjects, caregivers, and site personnel will not be informed of the randomized treatment assignments until the  implications of revealing such data for the overall LAM -002A study 
program have been determined by the project leader for the LAM -002A development program.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 39 of 91  Version 4 (16 October  2020)  8. STUDY DRUG INFORMATION, ADMINISTRATION, AND 
SUPPORT  
8.1. Blinded Study Drug ( LAM -002A and Placebo)  
8.1.1. Description  
LAM -002A is formulated in capsules containing 25 mg of apilimod dimesylate (equivalent to 
17.1 mg of apilimod free base, respectively). The capsule is Swedish orange, Size 0 and has a 
total fill weight of 175 mg. Inactive components in active capsul es are microcrystalline cellulose, 
silicified microcrystalline cellulose, anhydrous lactose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate.   
Placebo is formulated in capsules with identical appearance to the capsules containing active 
drug.  The inactive component in placebo capsules is microcrystalline cellulose. 
8.1.2. Source  
Study drug ( LAM -002A and placebo) will be provided by the study sponsor. 
8.1.3. Packaging and Labelling  
Study drug ( LAM -002A and placebo) is supplied in high density polyethylene (HDPE) bottles, 
induction sealed with child resistant closures. Each bottle contains 100 capsules. 
Labels for LAM -002A bottles meet all applicable FDA requirements.  
Concurrent stability studies are ongoing for lots used in current cli nical trials. Additionally, there 
is ICH stability data supporting 36 months of stability for drug product.  8.1.4. Shipping, Storage, and Stability  
The LAM‑002A and placebo capsules must be stored in a secure storage area, with limited 
access, at 2
o C to 8oC. 
 Study centers will be provided with initial and updated product stability data, when available. 
8.1.5. Dispensing  
A pharmacist or other qualified staff member will dispense bottles containing study drug 
(LAM -002A or placebo). Sufficient bottles will be dispensed  to the subject to provide an 
adequate drug supply for the duration of the planned treatment course.  
8.1.6. Return and Compliance Assessment  
After the completion of the treatment course, empty, partially used, or full bottles of study drug 
(LAM -002A or placebo) will be retrieved from the subject. The quantities of unused study drug 
and the date when these study supplies are returned by the subject should be recorded in the study drug accountability records. In addition, the subject’s dosing diary should be reviewed, any incomplete or inconsistent entries should be addressed, and the dosing diary should be copied. Returned capsules and bottles may be destroyed according to the site’s standard operating procedures (see Section  13.11).  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 40 of 91  Version 4 (16 October  2020)  8.1.7. Accountability  
See Section  13.11 for information regarding study drug ( LAM -002A or placebo) accountability.  
8.1.8. Overdose Precautions  
An overdose is defined as a dose taken (accidentally or intentionally) exceeding the overdose 
limit. In the case of a discrepancy in drug accountability, an overdose will be established only when it is clear that the subject has received an excess dose, or the investigator has reason to suspect that the subject has received an excess dose.  
There are limited data on the effects of LAM -002A overdose. LAM -002A doses as high as 
150 mg  BID (300 mg QD) were administered in a prior Phase  1 study. The adverse effects were 
primarily nausea, vomiting, and/or diarrhea that occurred acutely and tended to be trea tment-
limiting.  
For this protocol, an overdose of study drug is defined as ingestion of a total daily dose >300 mg QD (total daily dose) of LAM -002A (or the placebo equivalent). In a subject who experiences an 
overdose, consideration should be given as to whether study drug administration should be temporarily interrupted. If the overdose is recent and substantial, use of gastric lavage or induction of emesis may be considered but may not be necessary given the emetogenic nature of the drug at high doses. Observation for any symptomatic side effects should be instituted, and safety laboratory parameters should be followed closely (consistent with the protocol or more frequently, as needed). Appropriate supportive management should be instituted to mitigate adverse effects. The subject should remain under observation until adverse effects have 
recovered to baseline. There is no specific antidote for LAM -002A. 
The medical monitor should be contacted if a study drug overdose occurs. The occurrence of an overdose does not preclude further protocol therapy if the subject appears to be safely benefiting from treatment and the circumstances that led to the initial overdose are unlikely to recur.  
8.1.9. Inadvertent Exposure Precautions  
Based on available data, LAM -002A is not expected to be acutely toxic, irritating, or genotoxic 
at levels that are likely to result from inadvertent exposure. However, personnel handling the drug should use reasonable precautions to avoid eye contact, skin contact, inhalation, or ingestion of s tudy drug ( LAM -002A or placebo). Subjects should be instructed to keep the drug 
secured such that it is out of the reach of children and is not inadvertently taken by others. The LAM -002A investigator brochure can be consulted for further information regarding exposure 
and spill precautions. 
8.2. Study Drug Administration  
8.2.1. Drug Administration  
Study participants will be randomiz ed in a 1:1 ratio to receive study therapy, comprising either 
LAM -002A, 125 mg (five 25- mg capsules/dose) orally BID or placebo (five capsules/dose) 
orally BID for 10 days. 
Subjects are to self -administer study drug ( LAM -002A or placebo) starting on Day 1 and then 
continuously thereafter for the planned treatment course. Subjects should take the study drug at 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 41 of 91  Version 4 (16 October  2020)  approximately the same time each day, ideally at ~12- hour intervals ( e.g. ~8AM and ~8PM  
every day).  
On Day 1 , subjects should take the drug at the study center under the supervision of study 
personnel and the timing of study drug administration must be documented in the clinic notes 
and/or in the subject diary. While variations in dosing schedule may occur in the outpatie nt 
setting, the prescribed regimen should be followed as closely as possible.  
At each dose administration, the number of study drug ( LAM -002A or placebo) capsules 
corresponding to the appropriate dose of each drug should be swallowed whole with 100 to 200 mL (~4 to 8 ounces) of water. Subjects should be instructed not to bite or chew the capsules. 
In case of breakage of the capsules in the oral cavity, additional water should be taken as a rinse.  
8.2.2. Fed/Fasting Status  
On Day 1, subjects should ingest the study drug ( LAM -002A or placebo) while fasting (defined 
as no food with the exception of clear liquids for ≥2 hours before and ≥1  hour after dosing). With 
other doses, subjects may take the study drug without regard to fed or fasting status. 
8.2.3. Dose Schedule Interruptions and Vomited Doses  
Subjects who have a delay in administration of <6 hours should take the planned dose as soon as 
possible after the intended time of administration. For subjects who have a delay in administration of ≥6 hours, the dose should not be taken. The planned timing of subsequent drug administration should not be altered.  
Of note, the first (on -site) dose might occur at a time in the afternoon that would mean that the 
next scheduled (at home) dose is after midnight. In such a subject, the second dose may be taken 
in the morning of Day 2. Subsequent doses may then be adjusted to reflect 12-hour intervals following the time of administration of this second dose. For example, if the second dose is taken at 8AM, subsequent doses should fo llow a n 8AM -8PM dosing schedule.  
For subjects who vomit shortly after taking the study drugs, the vomited dose should not be replaced. The planned timing of subsequent drug administration should not be altered. 
8.2.4. Dose Modification Recommendations 
If a subje ct experiences an AE that is suspected to be related to the study drug, appropriate 
monitoring and supportive care ( e.g. antiemetics, antidiarrheals) should be instituted consistent 
with the nature of the event.  
If a subject experiences an intolerance to study drug that the investigator believes warrants dose 
modification . The study drug administration should be interrupted until the toxicity recovers to 
Grade ≤1 or baseline.  Subjects may then resume drug administr ation at the original dose level or 
at a reduced dose level of LAM -002A, 100 mg (four 25-mg capsules/dose) orally BID or placebo 
(four capsules/dose) orally BID. One further adjustments dose adjustment is permitted, to a reduced dose level of LAM -002A, 75 mg (three 25 -mg capsules/dose) orally BID or placebo 
(three capsules/dose) orally BID.  If the subject cannot tolerate study drug after a decrease in dose by 2 dose levels, then the subject should be discontinued from study drug therapy.  
After the study d rug dose is reduced, the dose should not be re- escalated, even if there is minimal 
or no toxicity with the reduced dose.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 42 of 91  Version 4 (16 October  2020)  Investigators may discuss modifications in the dosing regim en with the medical monitor.  
8.3. Emergency Unblinding  
Every attempt should be made to preserve the integrity of study drug ( LAM -002A/placebo) 
blinding. Unblinding in individual subjects who experience adverse events is rarely required to 
provide effective intervention and support. For subjects having adverse events or laboratory abnormalities that require drug cessation or medical inte rvention, the investigational staff should 
strive to provide necessary support to the subject without breaking the blind. In the exceptional circumstances that knowledge of the study drug assignment appears essential for providing appropriate medical management, the investigator should contact the medical  monitor to discuss 
the rationale for breaking the blind and the adverse consequences of the unblinding for the subject’s continued participation in the study. If the investigator still believes that unblinding is warranted, the investigator will be able to access the randomization system in order to obtain the treatment assignment for that subject. No randomization lists or other unblinding information will be provided to the site. After breaking the blind, the investigational site staff should record details regarding the reasons for breaking the blind and any adverse events leading to the breaking of the blind in the source documents and in the appropriate eCRF. 
If the site breaks the blind, that subject w ill be discontinued from study therapy ( LAM -002A or 
placebo) .  
8.4. Supportive Care  
8.4.1. General Recommendations 
Consistent with subject safety and comfort, administration of any prescription or over-the-
counter drug products other than study medication will be minimized during the study period. Subjects should be discouraged from use of herbal remedies, self -prescribed drugs, tobacco 
products, or street drugs during their participation in the clinical study and should be counseled to minimize use of alcohol or nonme dical marijuana.  
If considered necessary for the subject’s well -being, drugs for concomitant medical conditions or 
for symptom management may be given at the discretion of the investigator. The investigator’s decision to authorize the use of any drug other than study drug should take into account subject safety, the medical need, the potential for drug interactions, the possibility for masking symptoms of a more significant underlying event, and whether use of the drug will compromise interpretation of stud y endpoints. 
Subjects will be instructed about the importance of the need to inform the clinic staff of the use of any drugs or remedies (whether prescribed or over the counter ) before and during the study.  
Recommendations regarding specific types of conc omitant therapies, supportive care, diet, and 
other interventions are provided below. To minimize variations in supportive care, the recommended supportive care agents should be considered unless there is a medical rationale in a specific subject for use o f an alternative product.  
8.4.2. Antibiotics, Antifungals, and Antivirals  
Local practices or guidelines regarding infection prophylaxis may be followed. Subjects developing an intercurrent infection other than with SARS -CoV-2 during study drug treatment 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 43 of 91  Version 4 (16 October  2020)  may receive therapeutic antibacterial, antiviral, or antifungal drugs as needed. However, care 
should be taken to avoid or minimize concomitant administration of prophylactic or therapeutic antibacterial, antifungal, or antiviral, agents that are strong CYP3A4 inhibitors or inducers (see Section 8.4.9 and Section 15.1. Continuation of study therapy during treatment for an intercurrent infection is at the discretion of the investigator.  
8.4.3. Anti -SARS -CoV -2 Therapies  
At baseline and during study participation, study subjects may not receive chloroquine, hydroxychloroquine, BTK inhibitors, anti -SARS -CoV-2 vaccines, or other investigational anti-
SARS -CoV-2 drugs as long as they remain investigational. Subjects may not be receiving 
remdesivir, anti -IL-6 antibodies, therapeutic anti- SARS -CoV-2 antibodies, or post- convalescent 
plasma at baseline but may have such drug introduced as appropriate if they develop respiratory failure, cardiac failure, or other serious manifestations of COVID-19.  Continued study therapy together with these additional therapies is permitted at the discretion of the investigator.  Subjects 
are not allowed to participate concurrently in any other therapeutic clinical study.  
8.4.4. Anticoagulants 
Use of local anticoagulation or antithrombotic agents to maintain a venous access catheter is permitted. In addition, subjects who develop conditions that require anticoagulant therapy are permitted to receive such drugs and are not required to discontinue study participation. 
8.4.5. Antidiarrheals  
Subjects experiencing diarrhea (and/or abdominal cramping) may take loperamide at the earliest 
sign of a loose stool, an increase in bowel movements by 1 to 2 episodes compared to baseline, or an increase in stool volume or liquidity. The recommended regimen is 4 mg at the first onset of diarrhea, then 2 mg with each succeeding diarrheal stool until the subject is diarrhea -free for 
at least 12 hours.  
Additional antidiarrheal measures may be implemented at the discretion of the investigator. 
Subjects should also be instructed to maintain oral fluid intake to help sustain fluid and 
electrolyte balance during episodes of diarrhea.  
8.4.6. Antiemetics  
If antiemetics are needed, it is recommended that subjects be offered granisetron (Kytril®, Granisol®), as an oral tablet or solution every 6 to 8 hours as needed. If subjects have persistent nausea or vomiting, consideration can be given to a 10-mg subcutaneous injection of the extended release form of granisetron (Sustol®). Alternatively, application of a 31.3 -mg 
granisetron transdermal patch (Sancuso®) every 3 to 7 days can be considered. For t ransdermal 
prophylaxis, 24 to 48 hours may be necessary to allow a sufficient period to achieve effective granisetron systemic concentrations. Use of the serotonin antagonists, ondansetron (Zofran®, Zuplenz®) or dolasetron (Anzemet®) is also permitted.  
Aprepitant (Emend®) or netupitant+palonosetron (Akynzeo®) should be avoided because these 
drugs may inhibit CYP3A4 activity.  
Benzodiazepines may be considered.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 44 of 91  Version 4 (16 October  2020)  Corticosteroids can be introduced if other types of antiemetic agents are not sufficiently 
effective.  
8.4.7. Antihistamine, Antiinflammatory, or Antipyretic, Drugs  
Antihistamines ( e.g. cetirizine, diphenhydramine), and antiinflammatory/antipyretic drugs (e.g. 
acetaminophen [paracetamol], nonsteroidal anti- inflammatory drugs [NSAIDs]), may be used 
during the study, as medically warranted.  
8.4.8. Corticosteroids 
At study entry, subjects may be using systemic, intraarticular, inhaled, or topical corticosteroids. During study therapy, subjects may use systemic, intraarticular, enteric, inhaled, or topical corticosteroi ds as required for intercurrent conditions.  
8.4.9. Drugs with Drug -Drug Interaction Potential  
While clinical data are not yet available, in vitro data suggest that LAM -002A is metabolized by 
CYP3A. Based on these findings, protocol candidates who require therapy with the strong CYP3A4 inhibitors or inducers listed in Section 15.1 should not be enrolled into the study.  
During study participation, coadministration of study drug ( LAM -002A or placebo) with the 
strong CYP3A4 inhibitors or inducers listed in Section 15.1 should be avoided, if possible. 
However, a subject who develops a condition that may require use of such drugs is not required to permanently discontinue study drug. If medically appropriate, investigators may wish to use a therapeutic alternative that would not be expected to affect these enzymes.  
For subjects who require temporary use of a drug that does affect these enzymes (e.g. treatment 
with a systemic antifungal agent), study drug therapy can be temporarily interrupted and then 
resumed after completion of the  CYP3A4 inhibitor. For subjects who require initiation of chronic 
therapy with a drug that strongly affects these enzymes, investigators must consult with the medical monitor to consider the best course of action. If subjects do receive a CYP3A4 inhibitor concomitantly with study drug, they should be monitored closely for signs of LAM -002A 
toxicity.  
8.4.10. Drugs Known to Prolong the QT Interval  
Available nonclinical and clinical data do not suggest a high risk that LAM -002A will alter the 
QT interval at doses of ≤125 mg BID.  There is no specific restriction on use of drugs ( e.g. 
antiemetics) that might prolong the QT interval.  Drugs that are known to prolong QT Interval or 
cause Torsades De Pointes are listed in Section 15.2. 
8.4.11. Hematopoietic Support  
Red blood cell or platelet transfusions may be administered as medically indicated.  
8.4.12. Cardiopulmonary Support  
Study subjects should not be requiring supplemental oxygen or other cardiopulmonary support at 
baseline.  Subjects may be offered any medically necessary cardiopulmonary support during study participation. Study drug ( LAM -002A or pl acebo) may be continued at investigator 
discretion as long as the subject is able to be administered the study drug via the enteral route. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 45 of 91  Version 4 (16 October  2020)  8.5. Study Restrictions  
8.5.1. Breast Feeding  
There is no information regarding the presence of LAM -002A or its metabolites in hu man milk,  
the potential effects of the drug or its metabolites on the breastfed infant, or the potential effects 
of the drug or its metabolites on milk production. For these reasons, women who are nursing are not eligible to participate in this study. Lact ating women who do participate in this clinical trial 
must discontinue nursing during study therapy. 
8.5.2. Contraception/Reproduction  
In general toxicology studies, LAM -002A administration was not associated with adverse 
histopathological effects on organs of reproduction at exposures that are likely to be achieved 
clinically. However, no studies evaluating drug effects on reproductive function in animals or humans are available. Thus, subjects should be advised that the risks of LAM -002A for future 
reproduction are unknown. 
No nonclinical data or clinical data are available regarding LAM -002A effects during embryo -
fetal development. Accordingly, female subjects cannot be pregnant at the time of study entry 
and must be removed from study therapy if they do become pregnant. 
Sexually active females of childbearing potential must agree to use a protocol-recommended 
method of contraception during heterosexual intercourse from the start of the screening period until ≥30 days after the final dose  of study therapy. In the context of this protocol, a female 
subject is considered to be of childbearing potential unless she has had a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy; has medically documented ovarian failure (with serum estradiol and follicle -stimulating hormone [FSH] levels within the institutional laboratory 
postmenopausal range and a negative serum or urine beta human chorionic gonadotropin [βHCG]); or is menopausal (age ≥50 years with amenorrhea for ≥6 months).  
Sexua lly active male subjects who can father a child and are having intercourse with females of 
childbearing potential who are not using adequate contraception must agree to use a protocol-recommended method of contraception from the start of study therapy unti l ≥30 days after the 
final dose of the study therapy and to refrain from sperm donation from the start of study therapy until ≥90 days after administration of the final dose of study therapy. In the context of this protocol, a male subject is considered able to father a child unless he has had a bilateral vasectomy with documented aspermia or a bilateral orchiectomy.  
Protocol- recommended contraceptive methods are those that are considered highly effective (ie, 
can achieve a failure rate of <1% per year when  used consistently and correctly) [ CTFG  2014]. 
Such methods include:  
• Oral, intravaginal, or transdermal hormonal contraception that contains both estrogen and 
progestogen and is associated with inhibition of ovulation 
• Oral, injectable, or implantable progestogen- only hormonal contraception that is associated 
with inhibition of ovulation 
• Intrauterine device (IUD) 
• Intrauterine hormone -releasing system (IUS)  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 46 of 91  Version 4 (16 October  2020)  • Bilateral tubal occlusion  
• Vasectomy or vasectomized partner with documente d aspermia  
• Sexual abstinence ( i.e., refraining from heterosexual intercourse during the entire period of 
risk associated with the study drug administration considering that the reliability of sexual 
abstinence may be influenced by such factors as the duration of the clinical trial and the preferred and usual lifestyle of the subject ) 
It is advised that male subjects having heterosexual intercourse with a female partner of childbearing potential should use condoms plus an additional contraceptive method that together 
result in a failure rate of <1% per year. To avoid any potential study drug exposure to a partner, it is recommended that vasectomized men also wear condoms during sexual intercourse.  
8.5.3. Diet 
Because LAM -002A is a substrate of CYP3A4, subjects should be advised to avoid ingestion of 
grapefruit, grapefruit juice, or Seville oranges (which contains a potent CYP3A4 inhibitor) and should not use St. John’s wort, which is a potent CYP3A4 inducer. No other specific dietary restrictions are re quired. 
8.6. Duration of Study Drug Administration and Study Participation  
Subjects may receive study therapy ( LAM -002A or placebo) for as long as 10 days. However, 
the occurrence of any of the following events requires treatment discontinuation:  
• Subject request to withdraw from study treatment  
• Intolerable study drug toxicity despite appropriate supportive care and/or dose modification 
• The development of intercurrent illness or other substantial change in the subject’s condition 
or circumstances that would plac e the subject at unacceptable risk as determined by the study 
investigator in consultation with the medical monitor  
• Pregnancy or breastfeeding 
• Substantial noncompliance with study drug administration, study procedures, or study 
requirements in circumstances that increase risk or substantially compromise the interpretation of study results  
• Discontinuation of the study by the study center, the study sponsor, relevant regulatory 
agencies, or the IRB/IEC  
Subjects who discontinue study therapy will continue on study for acquisition of safety 
information through at least Day 28. Study follow -up will continue through Day 28 unless any of 
the following circumstances occurs:  
• Subject request to withdraw from follow -up 
• Subject lost to follow -up 
• Subject death 
• Terminatio n of the study by the study center, the study sponsor, relevant regulatory agencies, 
or the IRB/IEC  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 47 of 91  Version 4 (16 October  2020)  9. SAFETY ASSESSMENT  
9.1. Definitions  
9.1.1. Adverse Event  
An AE is any untoward medical occurrence in a clinical investigation subject administered a 
medicinal product; the event does not necessarily have a causal relationship with study drug administration or usage. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
In this study, any of the following events will be considered an AE: 
• Any complication that occurs as a result of a protocol-mandated procedure (e.g. 
venipuncture, ECG).  
• Any preexisting condition that increases in severity or changes in nature during or as a 
consequence of study drug administration. Worsening manifestations of the underlying 
infection (e.g.  increase in COVID- 19 manifestations) may be considered AEs in this study.  
• Any injury or accident. If a medical condition is known to have caused the injury or accident (e.g. a fall secondary to dizziness), the medical condition (dizziness) and the accident (fall) should be r eported as 2 separate AEs.  
• Any abnormality in physiological testing or a physical examination finding that requires clinical intervention or further investigation (beyond ordering a repeat [confirmatory] test).  
• Any laboratory (e.g. clinical chemistry, hem atology, urinalysis) or investigational 
abnormality ( e.g. ECG, X-ray) independent of the underlying medical condition that requires 
clinical intervention, results in further investigation (beyond ordering a repeat [confirmatory] test), or leads to investigational medicinal product interruption or discontinuation unless it is associated with an already reported clinical event. If the laboratory abnormality is part of a syndrome, the syndrome or diagnosis (e.g. anemia) not the laboratory result ( e.g. decreased 
hemoglobin) should be recorded.  
• A complication related to pregnancy or termination of a pregnancy (see Section  9.7.2 for 
additional information). 
None of the following events is considered an AE: 
• Laboratory abnormalities not requiring clinical intervention or further investigation. Such 
abnormalities will be captured as part of laboratory monitoring.  
• A diagnostic, medical,  or surgical procedure (e.g. surgery, endoscopy, tooth extraction, 
transfusion). However, the medical condition for which the procedure was performed should be reported if it meets the definition of an AE. For example, an acute appendicitis that begins 
during the AE reporting period should be reported as the AE and the resulting appendectomy 
should be recorded in the source documents.  
• A preexisting disease or condition or laboratory abnormality present or detected before the 
initial screening visit and that does not worsen. 
• An intervention not associated with an untoward medical occurrence (e.g. hospitalization for 
elective surgery or for social and/or convenience reasons).  
• An overdose without clinical sequelae. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 48 of 91  Version 4 (16 October  2020)  9.1.2. Serious Adverse Event  
An SAE is defined as an untoward medical occurrence that results in any of the following 
outcomes: 
• Death ( ie, all deaths occurring between signing of the consent form to within 30 days after 
last study drug administration), including deaths due to COVID-19 if no other event more 
satisfactorily ex plains the reason for death. Deaths that occur as a result of an AE that started 
during the study period should be reported. Death is not an SAE term; the reported AE should be the event that caused the death. Death is the outcome of this SAE.  
• Life-threatening situation (ie, with an immediate risk of death from the event as it occurred 
but not including an event that, had it occurred in a more serious form, might have caused death). 
• In-patient hospitalization or prolongation of existing hospital ization. Of note, an untoward 
medical occurrence that occurs during hospitalization is an AE but a complication that prolongs hospitalization is an SAE. In- subject hospitalization comprises formal admission to 
a hospital for medical reasons, for any length  of time, whether or not hospitalization extends 
overnight. However, hospital admissions or prolongations of hospitalization for administration of the study drug or procedures required by the study protocol, diagnostic observations or procedures, administration of concomitant or subsequent therapy for the cancer, logistical issues ( e.g. lengthy travel), or the convenience of the subject or clinical 
personnel are not considered serious.  
• Persistent or significant disability/incapacity.  
• Congenital anomaly/bir th defect in the offspring of a subject who received the investigational 
medicinal product. 
• Other medically significant event. Such events may not be immediately life -threatening or 
result in death or hospitalization, but based upon appropriate medical and scientific 
judgment, may jeopardize the subject,  or may require medical or surgical intervention to 
prevent one of the outcomes listed above. Examples of such events might include: 
o Allergic bronchospasm requiring intensive treatment in an emergency room or at home 
o New cancers or blood dyscrasias  
o Convulsions that do not result in hospitalization 
o Development of drug dependency or drug abuse 
9.1.3. Unexpected Adverse Event  
An unexpected AE is defined as an event that has a nature, severity, or specificity that is not consistent with the applicable investigator brochure, or that is symptomatically and pathophysiologically related to a known toxicity but differs because of greater severity or specificity. For example, under this definition, hepatic necrosis would be unexpected (by virtue of greater severity) if the investigator brochure only referred to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by virtue of greater specificity) if the investig ator brochure only listed cerebral vascular accidents. 
“Unexpected,” as used in this definition, refers to an adverse drug experience that has not been 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 49 of 91  Version 4 (16 October  2020)  previously observed and reported rather than an experience that has not been anticipated based 
on the pharmacological properties of the study drug. 
9.1.4. Treatment -Emergent Adverse Event  
A TEAE is defined as an AE that occurs or worsens in the period from the first dose of study 
drug administration to Day 28 of the study.  
9.1.5. Adverse Events of Special Interest  
There are no adverse events of special interest in this protocol.  
9.2. Eliciting Adverse Event Information  
The investigator is to report all directly observed AEs and all AEs spontaneously reported by the study subject. In addition, each study subject should be quest ioned about AEs at each scheduled 
study center visit or during any telephone contact with the subject. The type of question asked should typically be open-ended, e.g. “Have you had any new health problems?” or a similar type of query.  
9.3. Recording Adverse Ev ents 
All AEs will be assessed by the investigator or qualified designee and recorded in the electronic 
case report forms (eCRFs). The following considerations apply in collecting AE information: 
• Recognized medical terms (not colloquialisms, abbreviations, or jargon) should be used 
when recording AEs. Ideally the description should be consistent with MedDRA 
nomenclature. 
• The medical diagnosis (ie, disease or syndrome) should be recorded instead of signs and 
symptoms (e.g. pneumonia instead of shortness of breath, coughing, and fever). 
• Any sign or symptom considered as unrelated to an encountered disease or syndrome should 
be recorded as an individual AE ( e.g. if nausea and severe headache are observed at the same 
time, each event should be recorded as a separate AE).  
• If an AE resolves and reoccurs at a later date, a new AE must be documented and reported, as 
appropriate. 
The following information should be recorded: 
• Description as to whether the AE is serious, if applicable (see  Section   9.1.2) 
• The start date (date of AE onset)  
• The stop date (date of AE resolution) 
• The severity of the AE (see Section 9.4 ) 
• A description of the relatedness of the AE to the study drug or to a study procedure (see 
Section  9.5)  
• The action taken due to the AE 
• The outcome of the AE 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 50 of 91  Version 4 (16 October  2020)  9.4. Grading of the Severity of an Adverse Event  
The severi ty of AEs will be graded and reported using the CTCAE, Version 5.0.  
If a CTCAE criterion does not exist, the investigator should use the grade or adjectives: Grade  1 
(mild), Grade  2 (moderate), Grade 3 (severe), Grade 4 (life -threatening), or Grade 5 (fat al) to 
describe the maximum intensity of the AE. For purposes of consistency with the CTCAE, these 
intensity grades are defined in  Table 3 . 
Table 3. Grading of Adverse Event Severity  
Grade  Adjective  Description  
Grade  1 Mild  Sign or symptom is present, but it is easily tolerated, is not expected to 
have a clinically significant effect on the subject’s overall health and well- being, does not interfere with the subject’s usual function, and is 
not likely to require medical attention.  
Grade  2 Moderate  Sign or symptom causes interference with usual activity or affects 
clinical status  and may require medical intervention.  
Grade  3 Severe  Sign or symptom is incapacitating or significantly affects clinical status 
and likely requires medical intervention and/or close follow -up. 
Grade  4 Life-threatening  Sign or symptom results in a potential threat to life.  
Grad e 5 Fatal  Sign or symptom results in death.  
The distinction between the seriousness and the severity of an AE should be noted. Severity is a measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For example, a headache may be severe in intensity, but would not be class ified as serious unless it met one of 
the criteria for serious events (as listed in Section  9.1.2).  
9.5. Describing Adverse Event Relationship to Study Drug and Study Procedures  
The investigator will evaluate the causal  relationship of each AE to a study drug and/or to a 
study procedure (e.g. venipuncture or ECG evaluation) and record that relationship on the 
appropriate CRFs. Causality will be assessed considering whether the AE is reasonably related to 
the study drug or procedure or whether the AE is not reasonably related to the study drug or procedure considering the definitions in Table 4.  
It should be emphasized that the determination of the relationship of an adverse event to study 
drug ( LAM -002A or placebo) should be based on the presumption that the study subject is 
receivi ng active LAM -002A  even though the blind remains unbroken. As noted in Section 8.3, 
unblinding should be avoided unless absolutely necessary for a subject’s well- being; breaking 
the blind should not be performed merely to obtain enhanced certainty regarding the relationship of an adverse event to study drug.  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 51 of 91  Version 4 (16 October  2020)  Table 4.  Relationship of Study Drug to Adverse Event  
Relationship  Description  
Definite  A clinical event in which a relationship to the use of the study drug seems definite because 
of such factors as consistency with known effects of the drug; a clear temporal association 
with the use of the drug; lack of alternative explanations for the event; improvement upon withdrawal of the drug (de -challenge); and recurrence upon resumption of the drug 
(rechallenge).  
Probable  A clinical event in which a relationship to the study drug seems probable because of such 
factors as consistency with known effe cts of the drug; a reasonable temporal association 
with the use of the drug; lack of alternative explanations for the event; and improvement 
upon withdrawal of the drug (de -challenge).  
Possible A clinical event with a reasonable temporal association with administration of the study 
drug, and that is not likely to be explained by concurrent disease or other drugs or 
chemicals. Information on drug withdrawal may be lacking.  
Unlikely A clinical event with a temporal relationship to study dru g administration that makes a 
causal relationship improbable and for which other factors suggesting an alternative etiology exist. Such factors might include a known relationship of the clinical event to a concomitant drug, past medical history of a simila r event, the subject’s disease state, intercurrent illness, 
or environmental factors.  
Unrelated  A clinical event in which a relationship to the study drug seems improbable because of 
factors such as inconsistency with known effects of the study drug; lack of a temporal 
association with study drug administration; lack of association of the event with study drug 
withdrawal or rechallenge; and/or presence of alternative explanations for the event. 
Alternative explanations might include a known relationshi p of the clinical event to a 
concomitant drug, past medical history of a similar event, the subject’s disease state, 
intercurrent illness, or environmental factors.  
9.6. Adverse Event Reporting Period  
The start of the AE reporting for a study subject will coincide with the first administration of study drug for this study. After the first administration of study drug, all AEs (serious and nonserious, related and unrelated) should be reported. Unless a subject withdraws consent for follow -up, each subject must be followed until the end of the AE reporting period at Day 28 or 
when any ongoing drug- related AEs and/or SAEs have resolved or become stable. The 
investigator should use appropriate judgment in ordering additional tests as necessary to monitor the resolution of events. The medical monitor or the sponsor may request that certain AEs be followed longer.  
Investigators are not obligated to actively seek information regarding the occurrence of new 
SAEs beginning after Day 28. However, if the investigator learns of such an SAE and that event is deemed relevant to the use of LAM -002A , he/she should promptly document and report the 
event. A longer reporting period applies in the case of pregnancy (see Section  9.7.2).  
9.7. Study Center Reporting Requirements  
9.7.1. Adverse Event Reporting Requirements  
Classification of an event as serious or nonserious (see Section  9.1) determines the reporting 
procedures to be followed by the study center. Study center reporting requirements for AEs are summarized in  Table 5 . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 52 of 91  Version 4 (16 October  2020)  Table 5.  Study Center Reporting Requirements for Adverse Events  
Classification  Reporting Time  Reporting Action  
Serious  Within 24  hours of becoming aware 
of the event  E-mail report on designated SAE report form to 
the sponsor or designee [ a] and to the study center 
IRB, as per local IRB/IEC requirements  
Within 10 working days  E-mail copies of relevant source documents ( e.g. 
progress notes, laboratory and diagnostic test 
results, discharge summaries) [ b] to the sponsor or 
designee [ a].  
Per eCRF submission procedure  Record and submit information on appropriate 
eCRFs.  
Nonserious  Per eCRF submission procedure  Record and submit information on appropriate 
eCRFs.  
a. See contact information  provided . 
b. Subject name, address, and other personal identifiers should be obscured but without losing the traceability 
of a document to the study subject identifiers.  
Abbreviations: eCRF=case report form; IRB/IEC= institutional review board/independent ethics committee; 
SAE=serious adverse event  
For SAEs, in addition to completing the AE portion of the eCRF, an SAE report form must also 
be completed and emailed within 24 hours of first awareness of the event to the sponsor (or designee).  
Investigators must also submit written safety reports as required by the IRB/IEC within timelines 
set by local and regional regulations. The study site should retain documentation of the submission of expedited safety reports to the IRB/IEC, and their receipt. Study site personnel should not wait to receive comple te information or the investigator’s signature before notifying 
the sponsor (or designee) and the IRB/IEC of an SAE. 
The following minimum information is required: 
• Subject identification (i.e. subject number, sex, age) 
• Description of the SAE (diagnosis preferred, symptoms, etc.) 
• Study drug and causal relationship of the SAE to the study drugs or study procedures 
• Investigator name  
Collection of complete information concerning SAEs is extremely important. The  information in 
the AE portion of the eCRF and the SAE report form must match or be reconciled. Where the 
same data are collected, the forms must be completed in a consistent manner. For example, the same AE term should be used on both forms.  
All available and relevant supporting documentation (e.g. progress notes, pertinent laboratory 
and diagnostic test results, discharge summaries) should also be provided. The subject’s name, address, and other personal identity information should be obscured on any source documents (e.g. progress notes, nurses’ notes, laboratory and diagnostic test results, discharge summaries). The subject’s unique study number should be included on each page of any document provided.  
The sponsor (or designee) will review SAE reports for missing information and send queries to the site for resolution as indicated. The study site is responsible for obtaining pertinent follow -up 
information missing from initial reports and forwarding the information within 24  hours of 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 53 of 91  Version 4 (16 October  2020)  receipt to the sponsor (or designee). Follow-up information to the SAE should be clearly 
documented as “follow- up” in the SAE report form.  
The original SAE form and any follow-up forms must be kept on file at the study site. An SAE is 
followed until it is considered resolved, it returns to baseline, is chronically ongoing, or explained otherwise by the principal investigator. 
9.7.2. Pregnancy  
Each female subject should be instructed to inform the investigator immediately if she becomes 
pregnant at any time between the start of study screening until 30 days after the last administration of study drug.  Similarly, a male subject should also be in structed to inform the 
investigator immediately  if his female partner becomes pregnant during the same study period . 
The investigator should counsel the subject regarding the possible effects of study drug exposure on the fetus and the need to inform the study center, the medical monitor, and the sponsor (or designee) of the outcome of the pregnancy. 
Neither the pregnancy itself nor an induced elective abortion to terminate the pregnancy without 
medical reasons is considered an AE; such occurrences should b e reported on the appropriate 
pregnancy report forms. However, if the outcome of the pregnancy meets the criteria for classification as an SAE (ie, spontaneous abortion, induced abortion due to complications, stillbirth, neonatal death, or congenital anomaly [including that in an aborted fetus]), the investigator should follow the procedures for reporting SAEs (ie, report the event to the sponsor [or designee] and follow up by submission of the appropriate AE eCRFs (see Section  9.7.1).  
Additional information about pregnancy outcomes that are classified as SAEs includes:  
• Any spontaneous abortion, including miscarriage and missed abortion, will be reported as an SAE.  
• An induced therapeutic abortion to terminate any pregnancy due to complications or other medical reasons will be recorded as an SAE. The underlying medical reason for this procedure should be recorded as the AE term. 
• All neonatal deaths that occur within 1 month of birth should be reported, without regard to 
causality, as SAEs. In addition, any infant death after 1 month that the investigator assesses 
as possibly related to the in -utero exposure to the study drug should also be reported. 
• In the case of a live birth, the “normality” of the newborn can be assessed at the time of birth (ie, there is no required minimum follow -up of a presumably normal infant before the 
pregnancy outcome report eCRF can be completed). 
• The “normality” of an aborted fetus can be assessed by gross visual inspection unless there are pre-abortion laboratory findings suggestive of a congenital anomaly, in which case pathologic examination should be requested.  
Information regarding any pregnancy in a study subject or the female partner of a male subject must be documented on a pregnancy report form and forwarded to the sponsor (or designee)  for 
contact list ) within 24  hours of becoming aware of the pregnancy. Monitoring of the pregnancy 
in both female study subjects and female partners of male study subjects should continue until the conclusion of the pregnancy. For female partners of male study subjects, such monitoring 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 54 of 91  Version 4 (16 October  2020)  applies if the pregnancy occurs in the period from the subject’s start of study drug until 30 days 
after the subject’s last dose of study drug. The outcome of the pregnancy should be reported on the pregnancy outcome report form within 5 days of the conclusion of the pregnancy. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported to the sponsor (or designee). 
9.7.3. Contact Information for Reporting a n SAE or Pregnancy  
Contact information for reporting an SAE or Pregnancy  will be managed by the CRO. 
9.8. Sponsor Reporting Requirements  
Each SAE or special situation report received from the investigator will be evaluated by the 
sponsor (or designee). The sponsor (or designee) will assess the seriousness of the event (see Section  9.1.2), the expectedness of the event (see Section  9.1.3), and the relationship to 
participation in the study (see Section  9.5). The sponsor (or designee) will also indicate whether 
there is concurrence with the details of the report provided by the investigator.  
The sponsor (or designee) will provide information for reporting of suspected, unexpected, 
serious adverse reactions (SUSARs) to regulatory authorities worldwide consistent with relevant 
legislation or regulations, including the applicable US FDA CFR, the European Commission Clinical Trials Directive (2001/20/EC, and revisions), and other country specific legislation or 
regulations. SUSAR s will be reported to regulatory authorities within 7  calendar days for life  
threatening and fatal events, or 15 calendar days for all others. These timeframes begin with the first notification of the event from the reporting investigator to the sponsor (or designee), which represents the start of the regulatory clock (Day  0).  
The sponsor (or designee) will also provide all investigators with a safety letter describing the SUSAR. The  information will be provided by e -mail, fax, or overnight mail within 15  calendar 
days from Day  0. Investigators will be requested to provide written notification of the event to 
the relevant IRB/IEC as soon as is practical and consistent with local regulatory requirements and local institutional policy.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 55 of 91  Version 4 (16 October  2020)  10. LABO RATORY AND OTHER ASSESSMENTS  
10.1. Methods and Analytes  
Samples to be obtained and parameters to be analyzed are indicated in Table 6 . 
General safety laboratory assays (serum pregnancy test, serum chemistry, hematology,) will be 
performed using standard clinical pathology methods at Clinical Laboratory Improvement Amendments (CLIA)- certified laboratories associated with the study centers.   
For pharmacokinetic analyses, evaluation of LAM -002A blood concentrations will be performed 
using a validated assay at a contract laboratory designated by the sponsor.  
Viral load measurements from nasopharyngeal swabs at Days 1, and 4 will be conducted at 
Covance using the Quantification of C OVID-19 Viral Load using the 2019- nCoV Real -Time 
RT-PCR Viral Load assay on Applied Biosystems QuantStudio 7/12K Flex Real- Time PCR 
system (v2) assay.   The method has been validated to CAP/CLIA standards by Covance.  The quantitative assay does not have EUA, but the non-qualitative version of the assay developed by Covance does have EUA.  The limit of detection of the assay is set to the lower limit of quantification (LLOQ) of the quantitative 2019- nCoV CDC EUA assay using respiratory 
specimens which was determined using a synthetic RNA panel prepared at different target input 
levels at the lower end of the AMR. The panel was tested 5 times in tri plicate in at least one run.  
The LLOQ for 2019- nCoV CDC EUA assay for respiratory swabs is  3.348 Log10 copies/mL 
(2228 copies/mL). For values below the LLOQ that are still detected, a value of “detected” will 
be reported.  When no virus is detected a value of “undetected” will be reported.  
The method for saliva samples is currently completing similar CAP/CLIA validation at Covance. Details for both methods will be included in the Laboratory Manual. 
Pharmacodynamic and biomarker assessments will be conducted at contract laboratories 
designated by the sponsor. Clinical assessments (body weight and height, vital signs, oxygen saturation) will be obtained 
using standard clinical equipment available at each study center.  
ECGs will be performed at the clinical sites using equipment provided by the sites and will be interpreted by the sites.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 56 of 91  Version 4 (16 October  2020)  Table 6.  Laboratory and Other Parameters to Be Assessed  
Test/Procedure  Parameters  
Laboratory – Safety  
Urine (or serum) 
pregnancy test  Urine or serum β -HCG  
Serum chemistry  Sodium, potassium, chloride, bicarbonate, BUN, creatinine, glucose, calcium, 
phosphorus, magnesium, total protein, albumin, ALT, AST, ALP, CK, LDH, total bilirubin, uric acid.   
Hematology  Hematocrit, hemoglobin, eryt hrocyte count , absolute counts of leukocytes, 
neutrophils, lymphocytes, monocytes, eosinophils, basophils  
Platelet count  
Laboratory – Pharmacokinetic1 
Plasma pharmacokinetics  Plasma LAM -002A  concentrations (as assessed by validated bioassays)  (Worldwide 
Clinical Trials Early Phase Services/Bioanalytical Sciences, LLC., 8609 Cross Park 
Dr., Austin, TX 7 8754.) 
Retention of plasma for potential metabolite analyses  
Laboratory – Pharmacodynamic1 
Peripheral blood  and 
nasopharyngeal swabs for 
cellular 
pharmacodynamics  Plasma cytokines might  be analyzed for levels of IL -12, IL -23, IL-6, IFN-γ, IL-10 
and GM -CSF (additional cytokines may be analyzed in parallel)  
Target engagement biomarkers might  be assessed via RNA -seq or qRT-PCR  from  
RNA isolated from nasopharyngeal swabs and PBMC , or in plasma via established 
Luminex and or ELISA assays  
Laboratory – Disease -related  
SARS -CoV -2 
assessments Nasopharyngeal swab and saliva to determine SARS -COV -2 viral load using a 
qRT-PCR method . 
SARS -CoV -2 mutational 
analysis  Mutational profiling of SARS -CoV -2 viral genome might  be analyzed by RNA -seq 
or comparable technology1 
Genetic Polymorphism  in 
COVID -19 subjects  Analysis of germline DNA sequence polymorphisms  in genomic DNA isolated from 
blood or Nasopharyngeal swabs1   
Other  
Body weight/height  Weight in kilograms, height in centimeters  
Body temperature  Temperature in degrees Celsius  
Blood pressure  Diastolic and systolic blood pressure in mm Hg  
Oxygen saturation  % saturation  
12-lead ECG  Heart rate, cardiac intervals, wave form abnormalities, ectopy  
Abbreviations: ALP=alkaline phosphatase, ALT=alanine aminotransferase, AST=aspartate aminotransferase, 
BUN=blood urea nitrogen, CK=creatine kinase, DNA=deoxyribonucleic acid, ECG=electrocardiogram, LDH=lactate dehydrogenase, PCR=polymerase chain reaction, RNA=ribonucleic acid . 
1Samples will be collected for pharmacokinetic, immunogenicity, and genetic exploratory end points. The 
analysis for these exploratory endpoints is optional  
10.2. Sample Shipping, Storage, and Retention 
Routine clinical safety samples (for pregnancy test, serum chemistry, and hematology) will be 
analyzed at the clinical laboratory at the study center and will not be shipped. These samples will not be stored and will be discarded promptly after analysis.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 57 of 91  Version 4 (16 October  2020)  Other samples ( viral nasopharyngeal swab  samples; saliva; plasma for pharmacokinetics; blood 
and plasma for pharmacodynamics) will be prepared following the instructions outlined in a 
detailed clinical study laboratory manual.  
These samples will be shipped to the sponsor or the contract analytical laboratories using a 
shipping service designated by the sponsor and as specified in the clinical study laboratory 
manual. For the duration of the sample analysis campaign, samples will be s tored at these 
contract laboratory facilities or sent for long -term storage at a storage facility designated by the 
sponsor. Samples will be retained as described for study records (see Section  13.7 ). 
As described for other study records (see Section  13.7), copies of data relating to body weight 
and height, vital signs, oxygen saturation, etc. will be retained on file at the study centers. The sponsor may request copies of primary ECGs or radiography images (redacted of subject personal identifying information) for storage at the company.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 58 of 91  Version 4 (16 October  2020)  11. EFFICACY ASSESSMENTS  
11.1. Primary Efficacy  Endpoint : Viral Clearance at Day 4 
The primary efficacy outcome measure evaluates SARS-CoV-2 viral load at Day 4  for 
LAM -002A or placebo- treated subjects. SARS -CoV-2 viral load will be measured in 
nasopharyngeal specimens by a qRT -PCR method . Analysis will focus on log 10 viral load on 
Day 4  adjusted for baseline viral load at Day  1 in subjects with baseline viral load >105 
copies/mL .  
11.2. Secondary Efficacy Endpoint  
11.2.1. Clinical Efficacy  
An additional secondary efficacy endpoint measures the proportion of subjects treated with 
LAM -002A who progress ed to hospitalization or who died at Day 28 of randomization compared 
to those in the placebo arm.  
The need for referral for consideration for hospitalization will be assessed based on the CDC 
guidelines for presentation of mild/moderate, severe, and critical disease 
• Mild to moderate : mild symptoms ( fever [temperature ≥100.4], cough, sore throat, anosmia, 
malaise, headache, or muscle pain, gastrointestinal symptoms) up to mild pneumonia   
• Severe:  dyspnea, hypoxia, or >50% lung involvement on imaging 
• Critical: respiratory failure, shock, or multiorgan system dysfunction 
Severe and critical disease require hospitalization.  
The National Early Warning Score ( NEWS ) has demonstrated an ability to discriminate patients 
who are at risk of poor outcomes ( Smith  et.al., 2015) , and has been recommended by the World 
Health Organization ( WHO, 2020) . This score is based on 7 clinical parameters. The vital sign 
scores as measured by the NEWS  (Table 1 ) provides measures of dyspnea, hypoxia as well as 
other vital signs important to COVID-19 symptoms such as temperature and blood pressure.  
Vital signs related to COVID-19 illness will be monitored as specified in Table 7.  A composite 
score of vital sign parameters is calculated at baseline and at each visit. Change of NEWS from baseline will be used to assess resolution or progression of disease and decision for 
hospitalization. 
The following criteria will be used to determine need for hospitalization:  
• A composite NEWS >6, or  
• One NEWS parameter score of 3 (e.g. RR≥25, Oxygen saturation <91) , or 
• Respiratory failure , or  
• Severe presentations of other COVID-19 symptoms , or 
• ECOG Status  (see table in Section  15.3) 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 59 of 91  Version 4 (16 October  2020)  If the NEWS score increases during the follow -up visits, the subject will be followed more 
closely with subsequent day tele -health visits until the NEWS score improves or subject further 
declines, requiring hospitalization.  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 60 of 91  Version 4 (16 October  2020)  Table 7 National Early Warning Score (NEWS)  
 
Level of consciousness = alert (A), and arousable only to voice (V) or pain (P), and unresponsive (U).  
NEWS Composite Score 
NEWS = 0 -4 Low score: Assessment by a competent registered nurse who should decide if a 
change to frequency of clinical monitoring or an escalation of clinical care is 
required. 
NEWS = 5 -7 Medium Score: Urgent review by a clinician skilled with competencies in the 
assessment of acute illness.  
NEWS ≥ 7  High Score: Emergency assessment by a clinical/critical care outreach team with critical- care competencies and usually transfer of the patient to a higher 
dependency care area.  
11.2.2. Hospitalization: Clinical Status  
The secondary efficacy endpoint evaluates COVID-19 clinical status in cluding subjects who 
become hospitalized and continue LAM -002A /placebo treatment . Clinical status is  defined by 
the ordinal scale .  For subjects (who have the same ordinal score), control versus experimental 
arms will be compared based on percentage of subjects at each score on Day 2 8. 

Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 61 of 91  Version 4 (16 October  2020)  COVID-19 Severity Ordinal Scale scores in LAM -002A- treated and placebo -treated subjects 
will be determined at Day  28 based on the following scores: 
1. Not in the hospital 
2. Hospitalized, requiring low flow supplemental oxygen (such as nasal cannula)  
3. Hospitalized, not on invasive ventilation (such as 100% non- rebreather, BIPAP), (pre -ICU)  
4. Hospitalized, in the ICU, on invasive ventilation or ECMO 
5. Dead  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 62 of 91  Version 4 (16 October  2020)  12. STATISTICAL CONSIDERATIONS  
This is a double-blind placebo -controlled trial to determine the superiority of LAM -002A 
compared to placebo in reducing viral load  during a 10-day course of therapy.  
COVID-19 patients that fulfill all enrollment criteria and provide informed consent to study 
participation will have their baseline assessments performed and will be randomized  using a 
permuted block scheme (with variable block size) in a 1:1 ratio to one of the two groups: (1) 
LAM -002A, or (2) placebo.  
The study will include an early evaluation of safety, and an interim analysis . Full details of the 
statistical methods will be developed and outlined in the statistical analysis plan (SAP ) and filed 
with the study sponsor prior to database lock. 
12.1. Statistical Hypotheses  
All tests performed will be tests of superiority.  
For the primary efficacy endpoint, the hypothesis that L AM-002A results in a reduction in viral 
load compared to placebo  in the subgroup of participants with baseline nasopharyngeal viral load 
> 105 copies/mL  will be tested . 
12.2. Sample Size Determination  
The study is designed to have high power at a moderate significance level to detect a signal of 
benefit for the viral load outcome. The sample size calculation is based on the primary endpoint of interest: log
10 respiratory (naso pharyngeal swab) viral load at Day 4  post-randomization. 
Given the limited data on the variability of the change in log 10 viral load, the study is powered 
based on detecting a moderate standardized effect size of 0.3 using an analysis of covariance (ANCOVA), adjusting for baseline log
10 viral load. (NOTE: For ANCOVA, the effect size is the 
standard deviation of the treatment means divided by the pooled standard deviations of the observations. An ANCOVA standardized effect size of 0.3 is equivalent to a Cohen’s d of 0.60). To be conservative, a R -squared of 0 between the log
10 viral RNA at 4-days and baseline log 10 
viral RNA  was assumed .  With a power of 90%, and a type I error rate of 20% (2 -sided), it will 
be possible to detect the hypothesized 0.3 standardized effect si ze with 74 total patients  – 37 
patients per group with a 1:1 randomization.  We will enroll a sample size of 142 to assure that a 
sufficient number of participants with baseline viral load >105 copies/ml. The table below shows 
the power to detect an effect size of 0.3 given 10% loss to follow-up and various proportions enrolled with baseline viral load >10
5 copies ml.  
 Proportion of Enrolled Participants with >105 copies/ml  
 0.40 0.50 0.60 0.70 0.80 0.90 1.00 
Power to Detect 
Effect Size of 0.3  0.79 0.86 0.91 0.94 0.96 0.97 0.98 
 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 63 of 91  Version 4 (16 October  2020)  Based on available data regarding the distribution of viral load, it is conservatively estimated that 
≥50% of randomized participants will have a baseline viral load >105 copies/mL . The table 
above demonstrates that enrolling 142 will provide sufficient power even if the proportion with baseline viral load >10
5 copies/ml is as low as 40%.  The prevalence of this subgroup will be 
monitored and adjustments to overall sample size may be made if necessary.  
12.3. Analysis Sets  
12.3.1. Intention to Treat (ITT) Population 
The intention -to-treat (ITT) population includes all participants randomized according to their 
initial randomized assignment regardless of the treatment actually received.  
12.3.2. Antiviral Efficacy Analysis Population  
The antiviral efficacy analysis population will consist of all randomized participants with a 
baseline viral load >105 copies/mL. 
12.3.3. Per Protocol (PP) Population  
The per-protocol (PP) population includes all ITT participants who did not have any major 
protocol deviations. The final determination of the exclusion of subjects from the PP population 
will be made prior to the database lock.  
12.3.4. Safety Population 
The safety population will include all randomized subjects who received at least one dose of the 
study drug.  
12.4. Statistical Analyses  
12.4.1. General C onsiderations 
This is a double- blind placebo controlled randomized trial testing the superiority of LAM -002A 
compared to placebo for Day 4 vir al load  at the two -sided overall type I error rate of 0. 20. 
Secondary hypotheses will be described according to the appropriate summary statistics (e.g., 
proportions for categorical data, means with 95% confidence intervals for continuous data, 
median for time -to-event data). Diagnostic tests and sensitivity analyses will be performed. 
Parametric distributional assumptions will be checked. If assumptions fail, other distributions 
will be considered prior to transformations and non- parametric meth ods for sensitivity analysis. 
A statistical analysis plan (SAP) will be developed and filed with the study sponsor prior to 
database lock. 
12.4.2. Comparability of Baseline Characteristics.  
Distributions of baseline demographic and clinical characteristics will be summarized by 
intervention group. Comparability for continuous variables will be examined graphically and by summary statistics (means, medians, quartiles, etc.). Categorical variables will be examined by 
calculating frequency distributions. No inferential statistics will be calculated.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 64 of 91  Version 4 (16 October  2020)  12.4.3. Analysis of Primary Outcome : Viral Load in Nasopharyngeal Samples at Day 4 
The primary analysis will test whether the viral load in nasopharyngeal samples is lower at Day 4 
in those receiving LAM -002A compared to placebo. All participants in the antiviral efficacy 
analysis set (i.e. the subgroup with baseline viral load >105 copies/mL) will be included in the 
primary analysis. Viral load will be measured by a qRT-PCR test at Days 1 and 4. The analysis for the primary endpoint will focus on the log
10 viral RNA on Day 4. A repeated measures mixed 
model will be used to compare the two treatment groups. The mixed model will jointly model day 1 and day 4 viral load and will allow for the inclusion of all par ticipants with at least one 
viral load assessment  [Carpenter 2007]. The model will include fixed effects for treatment and 
age. Random effects will be included for subject and site. Linear contrasts will be used to 
compare the difference between groups for Day 4. This difference will be conditional on baseline viral load and is equivalent to an analysis adjusted for baselin e [Carpenter 2007]. 95% CIs will 
be estimated for treatment differences at Day 4. A supportive analysis will be conducted using the ITT population, stratified by baseline viral load >10
5 copies/mL vs. viral load ≤105 
copies/mL.  
12.4.4. Analysis of Secondary Outcomes 
The statistical and analytical methods that will be used to evaluate the secondary endpoints are 
described in this section.  
 Secondary Outcome: Hospitalization or Death Within 28 Days  
The proportion of those progressing to hospitalization or death within 28 days of randomization 
will be compared between treatment groups using logistic regression ( Ge 2011 ). All participants 
in the ITT population will be included in this analysis. Covariates in the analysis will include 
age. Site will be included as a random effect . The risk difference and 95% confidence interval 
will be estimated. Supportive analysis of this outcome will use the antiviral efficacy analysis population and the PP population.  
 Clinical Status (Disease Progression)  
The distribution of ordinal scale severity results will be summarized by treatment arm as 
percentages in the ITT population. A proportional odds model will be used to compare groups on 
this ordinal scale. The common odds ratio measures the effect size and is valid under the 
proportional odds assumption that will be verified via a goodness of fit likelihood ratio test. The model will include fixed effects for treatment, and age. Hypothesis tests for the mode l are nearly 
identical to the Wilcoxon Rank Sum test. Supportive analysis of this outcome will use the 
antiviral efficacy analysis population and the PP population. 
 Secondary Outcome: Oxygen Saturation (O2 sat)  
A logistic regression using generalized esti mating equations will be used compare the proportion 
of subjects at or above 95% oxygen saturation (O2 sat) between LAM -002A versus placebo as 
measured on Days 1, 4 and 11 in participants in the ITT population. Individuals requiring 
respiratory assistance, hospitalized or who died will be considered as having O2 sat <93%. Those 
who require baseline O2 will be excluded from the analysis. Supportive analysis of this outcome 
will use the antiviral efficacy analysi s population and the PP population. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 65 of 91  Version 4 (16 October  2020)  12.4.5. Exploratory E ndpoint s 
Analysis for exploratory endpoints will be defined in the study SAP or separate reports, as 
appropriate. 
12.4.6. Subgroup Analyses  
Heterogeneity of treatment effect (HTE) for the  primary and secondary progression to 
hospitalization or death outcome will be examined for the following subgroup variables:  days 
from onset of symptoms to randomization , NEWS score at randomization and sex (male vs. 
female).  HTE will be evaluated within a mixed  model for the primary outcome and a logistic 
regression for the secondary progression outcome. The models will include treatment, site, the subgroup variable,  and the interaction of the subgroup variable with time. Differences in means 
or risk  with 95% confidence intervals will be estimated for the treatment difference within each 
level of the subgroup variable. The significance test of the interaction will be used to formally test HTE at the two -sided 0.05 significance level. 
12.4.7. Plan for Missing Data 
Several strategies wil l be imposed to minimize the impact of missing data on conclusions. 
Prevention is the most obvious and effective manner to control bias and loss of power from missing data ( NRC 2010 ). This protocol will follow the intent to treat principle, requiring follow -
up of all subjects randomized regardless of the actual treatment received  (Lachin, 2000) . The 
only reasons for not considering a subject in analyses will be withdrawal of consent, a false 
positive test for SARS -CoV-2, or lost to follow-up. The informed consent and protocol will 
distinguish between treatment discontinuation and study withdrawal and the consent will also include a statement about the importance of continuing data collection despi te treatment 
discontinuation. Alternative contact information will be identified on entry into the study to 
minimize loss -to follow -up. Timely data entry combined with weekly missing data reports will 
trigger protocols for tracking and obtaining missing da ta items or outcome assessments. Despite 
these prevention efforts it is reasonable to assume missing data will occur. The primary analysis is valid under the assumption that missing data is missing at random (MAR). T he plausibility of 
this assumption will be evaluated by determining the extent of missing data and using logistic 
regression to identify factors associated with dropout. While differential rates of dropout 
between groups or high loss to follow-up are not expected , sensitivity analysis using pattern -
mixture and selection models under missing not at random (MNAR) assumptions will be 
performed to examine the robustness of conclusions of the primary analysis to missing data. 
12.4.8. Safety and Tolerability Analyses 
Adverse events (AEs) and serious adverse events (SAEs) will be categorized by severity and 
relation to study drug using the Safety population. AEs will be classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.  
Safety endpoints including SAEs, Grade 3 and 4 adverse events and signs compatible with 
cardiac arrhythmias, allergic reactions, gastrointestinal, hepatobiliary, eye and ear, blood and lymphatic system disorders and acute exacerbation of lung disorders will be described by 
treatment group.  Each AE will be counted once for a given participant and graded by severity 
and relationship to COVID-19 or study intervention. AEs will be presented by system organ 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 66 of 91  Version 4 (16 October  2020)  class, duration (in days), start - and stop- date. Adverse events leading to premature 
discontinuation from the study intervention and serious treatment- emergent AEs will be 
presented in tables and listings. 
Differences between treatment groups for safety outcomes will be tested at the 0.05 (2 -sided 
level of significance) without correction for multiple testing.  
 Adverse Events  
Treatment -emergent AEs and non-TEAEs (those occurring prior to administration of study 
medication or that first occurred prior to study drug administration and did not worsen in 
frequency or severity) will be listed. TEAEs will be defined as AEs that occur on or after the 
date and time of study drug administration, or those that first occur pre-dose but worsen in 
frequency or severity after study drug administration. AEs will be followed -up until complete 
resolution, or until the PI or Sub- Investigator judg es safe to discontinue follow -up.  
The incidence of TEAEs will be summarized using the safety population. The MedDRA® dictionary Version 23 will be used to classify all AEs reported during the study by system organ class (SOC) and preferred term (PT). Incidence of subjects who experienced TEAEs will be 
presented by treatment and overall, SOC, PT, by Investigator- assessed relationship and also by 
severity. Each subject may only contribute once to each of the incidence rates, for a TEAE 
following a given trea tment, regardless of the number of occurrences; the highest severity or 
highest relationship will be presented, as appropriate. In each table, SOC will be presented in descending order of overall incidence rate in terms of frequency of subjects and then in frequency of events (alphabetical order will be used in case of equal rates). For each SOC, PT 
will be presented the same way.  
Incidence of TEAEs (number of events) will also be presented by treatment and overall, by SOC, 
and PT, by Investigator- assessed relationship and severity.  
Severity of AEs will be rated according to CTCAE criteria as outlined in Section 9.4 and defined 
in Table 3  as Grade 1 (m ild), Grade 2 (moderate), Grade 3 (s evere ), Grade 4 (life -threatening) 
and Grade 5 (fatal).  
 Laboratory Parameters 
Clinical laboratory tests including biochemistry, hematology, and other screening tests, will be performed as listed in Table 6 , and at time points spec ified in the SoA  (Table  1). Microscopic 
examination will be performed on abnormal findings. Listings of all clinical laboratory results 
will be provide d with the abnormal values flagged with "L" (Below normal range) and "H" 
(Above normal range) for continuous parameters, and “N” (Normal Range) for categorical 
parameters.  
Descriptive statistics (mean, median, SD, Min, Max, and sample size) for each clinic al laboratory 
test (continuous variables) will be presented. Change from baseline to study exit will also be presented. For a given laboratory test, any value (scheduled or unscheduled), prior to the first 
dosing will replace any missing screening value (if scheduled value is missing). However, 
unscheduled results will not be included in the summary tables. For categorical variable, the number of subjects (frequency and percentage) will be tabulated by results (e.g., negative, 
positive, trace, etc.). A summary table of shifts from screening to study exit will be provided. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 67 of 91  Version 4 (16 October  2020)  Results from repeat tests will not be included in the summary statistics unless the repeat was 
required (and documented as such) due to technical reasons or an invalid initial result.  
12.4.9. Other  Safety Analyses 
Any other safety analysis will be made on the  safety population. 
12.5. Interim Analyses  
The study will incorporate an interim analysis for safety after the first 30 subjects (15 on LAM -002A and 15 on placebo) have completed treatment and have been followed up to Day 11. 
Recommendations from an independent Data Safety Monitoring Board (DSMB) w ill be used for 
decision of early termination or design adaptations (see table of Death Trigger Study Termination below). No formal assessment of futility or efficacy will be performed at this first 
interim report.   
Subsequent interim DSMB reports will be reviewed with no more than 6 months between 
reviews. In addition to safety, at 50% enrollment the DSMB will review the proportion of 
participants that have a baseline viral load of >10
5 copies/ml. Based on this proportion the 
DSMB may recommend an increase in sample size to assure a sufficient number of participants 
in the subgroup for primary analysis. If a recommendation for a sample size increase is being considered, futility will be examined via conditional power to assist in this determination. Details  
will be provided in the SAP.  
The first interim analysis for safety will be conducted and presented to the DSMB when 15 participants in each treatment arm have reached 1 1 days following randomization. At this 
review, it is proposed that the study be stopped if mortality is significantly higher in the 
LAM -002A arm compared to placebo arm based on a Fisher’s exact test. Table 8 shows the 
differences in deaths between the LAM -002A and placebo arm that will prompt discontinuation 
of the study.  
Table 8.  Death Boundary  for Study Termination  
Placebo Deaths , n LAM -002A  Deaths, n  Difference  
(LAM -002A  – Placebo)  Fisher’s Exact P-Value  
0 5 5 0.042  
1 7 6 0.035  
2 8 6 0.05 
3 10 7 0.025  
4 11 7 0.027  
5 12 7 0.025  
6 13 7 0.021  
7 13 6 0.050  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 68 of 91  Version 4 (16 October  2020)  13. STUDY ADMINISTRATION AND RESPONSIBILTIES  
13.1. General Investigator Responsibilities  
The principal investigator must ensure that:  
• He or she will personally conduct or supervise the study. 
• His or her staff and all persons who assist in the conduct of the study clearly understand their 
responsibilities and have their names included in the relevant Study Personnel documents. 
• The study is conducted according to the protocol and all applicable regulations. 
• The protection of each subject’s rights and welfare is maintained.  
• Signed and dated informed consent and, when applicable, permission to use protected health information are obtained from each subject before conducting study procedures. If a subject withdraws permission to use protected health information, th e investigator will obtain a 
written request from the subject and will ensure that no further data be collected from the subject. 
• The consent process is conducted in compliance with all applicable regulations and privacy 
acts. 
• The IRB/IEC complies with app licable regulations and conducts initial and ongoing reviews 
and approvals of the study. 
• Any amendment to the protocol is submitted promptly to the IRB/IEC.  
• Any significant protocol deviations are reported to the medical monitor, the sponsor, and the IRB/I EC according to the guidelines at each study center.  
• eCRF pages are completed in a timely fashion.  
• All SAEs are reported to the sponsor (or designee) within 24 hours of knowledge and to the 
IRB/IEC per IRB/IEC requirements.  
• All safety reports are submitted  promptly to the IRB/IEC.  
13.2. Protocol Compliance  
The investigator is responsible for ensuring the study is conducted in accordance with the procedures and evaluations described in this protocol. 
13.3. Compliance with Ethical and Regulatory Guidelines  
The investigator will ensure that this study is conducted in accordance with ICH guidelines, or 
with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the study subject. For studies conducted under a US IND, the investigator will ensure adherence to the basic principles of GCP as outlined in 21 CFR 312, subpart D, “Responsibilities of Sponsors and Investigators,” 21 CFR, Part 50, 1998, and 21 CFR, Part 56, 1998. 
This study is also subject to and will be conducted in accordance with 21 CFR, Part 320, 1993, 
“Retention of Bioavailability and Bioequivalence Testing Samples.” 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 69 of 91  Version 4 (16 October  2020)  Because this is a “covered” clinical trial, the investigator will ensure adherence to 21 CFR, 
Part 54, 1998; a covered clini cal trial is any “study of a drug or device in humans submitted in a 
marketing application or reclassification petition subject to this part that the applicant or FDA relies on to establish that the product is effective (including studies that show equivalence to an effective product) or that make a significant contribution to the demonstration of safety.” This requires that investigators and all sub -investigators must provide documentation of their financial 
interest or arrangements with the sponsor, or proprietary interests in the drug being studied. This documentation must be provided before participation of the investigator and any sub- investigator 
in the trial. The investigator or sub -investigator agrees to notify the sponsor of any change in 
reportable financial interests during the study and for 1 year following completion of the study. Study completion is defined as the date that the last subject has completed the protocol-defined activities.  
13.4. Institutional Review Board/Independent Ethics Committee (IR B/IEC)  
This protocol and any accompanying material to be provided to the subject (such as advertisements, subject information sheets, or descriptions of the study used to obtain informed consent) will be submitted by the investigator to an IRB/IEC. Approva l from the IRB/IEC must 
be obtained before starting the study and should be documented in a letter from the IRB/IEC to the investigator specifying the protocol number, protocol version, protocol date, documents reviewed, and date on which the committee met and granted the approval. A signed protocol approval page, a letter confirming IRB/IEC approval of the protocol and informed consent, and a statement that the IRB/IEC is organized and operates according to GCP and the applicable laws and regulations must be forwarded to the sponsor before screening subjects for the study. Additionally, study centers must forward a signed Form FDA 1572 (Investigator Obligation Form) to the sponsor before screening subjects for study enrollment. 
Any modifications or amendments made to the protocol or informed consent document after 
receipt of the initial IRB/IEC approval must also be submitted to the IRB/IEC for approval 
before implementation. Only changes necessary to eliminate apparent immediate hazards to the subjects may be initiated prior to IRB/IEC approval. In that event, the investigator must notify the IRB/IEC, the medical monitor, and the sponsor in writing within 5 working days after implementation. If a change to the protocol in any way increases the risk to the subject or changes the scope of the study, then written documentation of IRB/IEC approval must be received by the sponsor before the amendment may take effect. Additionally, under this circumstance, information on the increased risk and/or change in scope must be provided to subjects already actively participating in the study, and they must read, understand, and sign any revised informed consent document confirming willingness to remain in the trial.  
The investigator shall submit a progress report at least o nce yearly to the IRB/ IEC and  must 
provide a copy to the sponsor. As soon as possible after completion or termination of the study, the investigator will submit a final report to the IRB/IEC and to the sponsor. This report should include the dates of initi ation and completion of the trial, a description of any changes in study 
procedures or amendments to the protocol, any deviations from the protocol, the number and type of subjects evaluated, the number of subjects who discontinued (and the reasons for discontinuation), the number of subjects who completed the trial, and the results of the trial, including a description of any AEs. The sponsor will assist the investigator in the preparation of this report, as needed. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 70 of 91  Version 4 (16 October  2020)  13.5. Informed Consent  
The investigator, or a designee (designee must be listed in the relevant in the relevant study 
personnel documents), must explain to each subject the purpose and nature of the study, the study procedures, the possible adverse effects, and all other elements of consent as defined  in 
21 CFR Part 50 and other applicable national and local regulations governing informed consent. Each subject must provide a signed and dated informed consent before enrollment into this study. Signed consent forms must remain in each subject’s study fil e and be available for 
verification by study monitors at any time.  
A copy of the IRB/IEC -approved informed consent must be forwarded to the sponsor or designee 
for regulatory purposes.  
13.6. Confidentiality  
Every effort will be made to maintain the anonymity and confidentiality of all subjects during 
this clinical study. However, because of the experimental nature of this study drug, the investigator agrees to allow the IRB/IEC, representatives of the sponsor and its designated agents, and authorized employees of appropriate regulatory agencies to inspect the facilities used in this study and, for purposes of verification, allow direct access to the study center records of all subjects enrolled into this study. This includes providing by fax, email, or regular mail de-identified copies of clinical, laboratory, ECG, radiology, pathology, and/or other test results when requested by the sponsor. A statement to this effect will be included in the informed consent and a permission form authorizing the use of protected health information will also be included. 
In accordance with local and national subject privacy regulations, the investigator or designee 
must explain to each subject that in order to evaluate study results, the subject’s protected health information obtained during the study may be shared with IRB/IECs, the sponsor and its designees, and regulatory agencies. It is the investigator’s or designee’s responsibility to obtain 
written permission to use protected health information from each subject. If a subject withdraws 
permission to use protected health information, it is the investigator’s responsibility to obtain the withdrawal request in writing from the subject and to ensure that no further data will be collected from the subject. Any data collected on the subject before withdrawal will be used in the analysis of study results. The sponsor will only use or disclose the subject’s protected health information as defined in the informed consent document. 
The investigator must assure that each subje ct’s anonymity will be strictly maintained,  and that 
each subject’s identity is protected from unauthorized parties. Only subject initials, date of birth, 
and an identification code (but no subject names) should be recorded on any form or biological sample submitted to the IRB/IEC, to the sponsor or its designees (e.g. laboratories), or to 
regulatory authorities. However, sufficient information must be retained at the study center to permit sample data and data in the database to be connected with the uniqu e subject number 
assigned to each study participant.  
The investigator agrees that all information received from the sponsor, including but not limited to the study drug, the investigator brochure, this protocol, the eCRFs, and any other study information r emain the sole and exclusive property of the sponsor during the conduct of the 
study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 71 of 91  Version 4 (16 October  2020)  written consent from the sponsor. The investigator further agrees to take all reasonable 
precautions to prevent the disclosure by any employee or agent of the study center to any third party or otherwise into the public domain.  
13.7. Study Files a nd Retention of Records and Biological Samples  
The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified by the IRB/IEC, representatives of the spon sor and its designated agents, and authorized employees of appropriate 
regulatory agencies. These documents should be classified into at least the following 2 categories: (1) investigator’s study file, and (2) subject clinical source documents.  
The invest igator’s study file will contain the protocol/amendments, eCRF and query forms, the 
IRB/IEC and governmental approval with correspondence, signed informed consent documents, drug accountability records, staff curriculum vitae and authorization forms (e.g. Form FDA 1572), and other appropriate documents and correspondence pertaining to the conduct of the study.  
The required source data referenced in the monitoring plan for the study should include 
sequential notes containing at least the following information for each subject:  
• Subject identification (name, date of birth, gender)  
• Documentation that the subject meets eligibility criteria, e.g. history, physical examination, and confirmation of diagnosis (to support inclusion and exclusion criteria) 
• Participation in trial (including trial number)  
• Trial discussed and date of informed consent 
• Dates of all visits  
• Documentation that protocol- specific procedures were performed  
• Results of efficacy parameters, as required by the protocol  
• Start and end date ( including dose regimen) of study drug (including relevant drug 
dispensing information)  
• Record of all AEs and other safety parameters (including start and end date, causality and 
intensity)  
• Concomitant medications (including start and end date and dose if r elevant dose changes 
occur) 
• Date of trial completion and reason for discontinuation, if applicable  
All clinical study documents must be retained by the investigator until at least 2 years after the 
last approval of a marketing application in an ICH region (i.e. the United States, Europe, or Japan) and until there are no pending or contemplated marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified or for 15 years, whichever is longer. Investigators may be required to retain documents longer if required by applicable regulatory requirements, by local regulations, or by an agreement with the 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 72 of 91  Version 4 (16 October  2020)  sponsor. The investigator must notify the sponsor and obtain written approval from the sponsor 
before destroying any clinical study records. The investigator will promptly notify the sponsor in the event of accidental loss or destruction of any study records. The sponsor will inform the investigator of the date that study records may be destroyed or returned to the sponsor. 
The sponsor must be notified in advance and must provide express written approval of any 
change in the maintenance of the foregoin g documents if the investigator wishes to move study 
records to another location or assign responsibility for record retention to another party.  
If the investigator cannot guarantee this archiving requirement at the study center for any of the documents, special arrangements must be made between the investigator and the sponsor to store 
these in sealed containers outside of the study center so that they can be returned sealed to the investigator in case of a regulatory audit. When source documents are requ ired for the continued 
care of the subject, appropriate copies should be made for storage outside of the study center. 
Biological samples retained by the investigator will be stored and maintained by the investigator 
until notification is received from the  sponsor that the retained samples and records no longer 
need to be retained. The investigator must obtain written permission from the sponsor before disposing of any retained samples. The investigator should promptly notify the sponsor in the event of accidental loss or destruction of any study samples. With the permission of the sponsor, the retained samples may be transferred to an acceptable designee, such as another investigator, another institution, a contract laboratory, a contract storage site, or t o the sponsor.  
13.8. Subject Screening Log  
The investigator must keep a record that lists all subjects who signed the informed consent (including those who did not undergo screening). For those subjects who declined to participate or were subsequently excluded from enrollment, the reasons for not enrolling in the study must be described.  
13.9. Modifications of the Protocol or Informed Consent Documents  
Protocol modifications, except those intended to reduce immediate risk to study participants, w ill 
be made only by the sponsor. All protocol modifications must be submitted to the IRB/IEC in accordance with local requirements. Except as noted in Section  13.4, IRB/IEC approval must be 
obtained before changes can be implemented.  
Informed consent documents cannot be changed without prior approval by the sponsor and the 
study center IRB/IEC.  
13.10. Case Report Forms  
Authorized study center personnel wil l complete eCRFs designed for this study according to the 
completion guidelines that will be provided. An eCRF is required and must be completed for each enrolled subject, with all required study data accurately recorded such that the information matches the data contained in medical records ( e.g. physicians’ notes, nurses’ notes, study center 
charts, or other study- specific source documents). The investigator will ensure that the eCRFs 
are accurate, complete, legible, and completed in a timely fashion after each subject’s visit. The investigator will ensure that source documents that are required to verify the validity and completeness of data transcribed on the eCRFs are never obliterated or destroyed. As required by the protocol, eCRFs should also be completed for those subjects who fail to complete the study 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 73 of 91  Version 4 (16 October  2020)  (even during the screening period). If a subject withdraws from the study, the reason must be 
noted on the eCRF and thorough efforts should be made to clearly document outcome.  
The eCRFs for this stu dy will exist within a web -based electronic data capture (EDC) system. 
After the investigator or the investigator’s designees (e.g. research coordinators) have been 
appropriately trained, they will be given access to the EDC system and will enter the data required by the protocol into the EDC system. Any change of data will be made via the EDC system, with all changes tracked by the system to provide an audit trail.  
The eCRF must be completed and signed by the principal investigator or sub- investigator (as 
appropriate) within a reasonable time period after data collection. This signature serves to attest that the information contained in the eCRF is true.  
13.11. Study Drug Accountability  
The disposition of all study drug ( LAM -002A and placebo) should be documented from the time 
of receipt at the study center through subject administration. An investigational drug accountability log must be maintained for drug accountability. It is acceptable to use a protocol-specific form or a study center form that captures the relevant information. Within the drug accountability log, the responsible study center personnel must maintain accurate records of the receipt of all study drug ( LAM -002A and placebo) shipped by the sponsor (or its designee), 
including, but not limited to, the date received, bottle number, amount received, pertinent details about the condition of the study drug upon receipt based on visual inspection, and the disposition of the drug (e.g. to storage). If a study drug shipment arrives damaged, or if there are any other complaints relating specifically to the drug, a product complaint should be emailed to the sponsor or the sponsor’s representative. Study drug accountability records must also be maintained that include the subject number to whom the study drug is administered, and the date, quantity and bottle number of the study drug administered. 
Study personnel must ensure that study drug is kept in a secure locked area with access limited to 
authorized personnel. The study drug must not be used outside the context of this protocol. 
Under no circumstances should the investigator or study center personnel supply study drug to other investigators, subjects, or clinics, or allow the study drug to be used other than as directed by this protocol without the prior authorization from the sponsor.  
Depending upon the decision of the sponsor, remaining unused study drug supply will be 
returned to the sponsor or its designee after the study is completed or will be discarded or destroyed at the study center. After investigational product accountability has been performed, study drug disposal can occur per instructions provided by the sponsor. If the study drug is 
discarded or destroyed at the study center, standard institutional policy should be followed. At study initiation, the monitor will evaluate the study center’s standard operating procedure for study drug disposal/destruction in order to ensure that it complies with sponsor requirements. At the end of the study, following final drug inventory reconciliation by the monitor, the study center will dispose of and/or destroy all unused study drug supplies, including empty containers, per instructions provided by the sponsor. If the study center cannot meet sponsor requirements for disposa l, arrangements will be made between the study center and the sponsor or its 
representative for destruction or return of unused study drug supplies. 
All study drug supplies and associated documentation will be periodically reviewed and verified 
by the study monitor over the course of the study. Study drug accountability records must be 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 74 of 91  Version 4 (16 October  2020)  readily available for inspection by the study monitor or other representatives of the sponsor or by 
regulatory authorities.  
13.12. Monitoring  
Representatives of the sponsor or its d esignee will monitor this study until completion. 
Monitoring may be conducted through telephonic, web-based, or personal visits with the investigator and study center staff as well as any appropriate communications by email, regular mail, or fax. The monit or is responsible for routine review of the eCRFs at regular intervals 
throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The purpose of monitoring is to ensure compli ance 
with the protocol and the quality and integrity of the data.  
In accordance with GCP, the study monitor must have direct access to the investigator’s source 
documentation in order to verify the data recorded in the eCRFs for consistency. The investiga tor 
agrees to cooperate with the monitor to ensure that any problems detected in the course of these monitoring visits are resolved.  
13.13. Inspections  
The source documents for this trial must be made available to appropriately qualified personnel from the sponsor or its representatives, to IRB/IECs, and to regulatory authority or health authority inspectors as a part of their responsibility to protect human subjects in research. The investigator agrees to provide access to records, facilities, and personnel for the effective conduct of any inspection or audit to representatives of the sponsor and regulatory agencies. It is important that the investigator and relevant institutional personnel are available during monitoring visits and possible audits or inspections and that sufficient time is devoted to the process. If the investigator is notified of an inspection by a regulatory authority the investigator agrees to notify the sponsor immediately.  
13.14. Data Management 
Electronic data capture will be used to enter study data into eCRFs and to transfer the data into a 
study- specific electronic database. During the data collection process, automated quality 
assurance programs will be used to identify missing data, out-of-range data, and other data inconsistencies. Requests f or data clarification or correction will be forwarded to the 
investigative study center for resolution. As appropriate, eCRFs, listings, tables, and SAS datasets will be provided to the study centers for review.  
Quality assurance and quality control system s will be implemented and maintained according to 
written standard operating procedures to ensure that the data are generated, recorded, and reported in compliance with the protocol, GCP, and applicable regulatory requirements. Data collection and storage systems will provide audit trail, security mechanisms, and electronic signature capabilities that meet the requirements of FDA Title 21 of CFR Part 11 regarding electronic records and electronic signatures.  
Data security will be controlled through appropr iate and specific restriction of access only to data 
and systems required by individual users to accomplish their roles in the data management process. Individual login and password protections will be employed at study centers and at the sponsor or its de signee. The database will exist on physically secured servers. Data backups will 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 75 of 91  Version 4 (16 October  2020)  be done regularly and will be stored in separate facilities. Printed documents relating to the study 
will be secured when not under review.  
13.15. Clinical Trial Insurance  
The spons or will secure clinical trial insurance. An insurance certificate will be made available 
to the participating study centers before study initiation. 13.16. Communications with Regulatory Authorities  
The sponsor (or its designee) will assume responsibility for int eractions with the FDA and any 
other relevant regulatory authorities. The sponsor will maintain an IND for LAM -002A in 
support of the study in the US and will maintain similar regulatory applications with other 
regulatory authorities as required for conduc t of the study. In fulfilling these responsibilities, the 
sponsor (or a designee) will collect and assemble all required regulatory documents ( e.g. Form 
FDA 1572, investigator financial disclosure forms, protocol and protocol amendments, investigator brochures, informed consent documents, annual reports) as required by regulation. The sponsor (or a designee) will also assume responsibility for AE rep orting to regulatory 
authorities (as described in Section  9.8). 
13.17. Public Notification of Study Conduct  
Consistent with Section 113 of the Food and Drug Modernization Act of 1997 (FDAMA) and to ensure meeting the requirement of the International Committee of Medical Journal Editors (ICMJE) as a condition of consideration for publication of study results, the sponsor will register this protocol at the ClinicalTrials.gov website (or equivalent). If the protocol is registered at ClinicalTrials.gov, the sponsor will appropriately update the information at the website relating to study design and conduct during the course of the study. In order to facilitate this process, 
investigators will need to supply the sponsor with appropriate contact information for study center personnel.  
13.18. Study Reporting and Publication  
The sponsor may make information obtained during this study available in order to further the scientific or business needs of the company or as required by law or regulation. In this regard, the sponsor may provide study information to private or public organizations (e.g. business partners, collaborators, consultants, CROs, investors, other physicians who are conducting similar studies, funding organizations, regulatory authorities, or other government authorities). The results may also be used for papers, abstracts, posters or other material presented at scientific meetings or published in profess ional journals or as part of an academic thesis.  
The sponsor will prepare a clinical study report for submission to relevant regulatory agencies. The sponsor will ensure that the report meets the standards set out in the ICH Guideline for Structure and Con tent of Clinical Study Reports (ICH E3). An abbreviated report may be 
prepared in certain cases, as appropriate.  
The sponsor intends that the data from this study will be presented and published. Because the data will ultimately  be part of a multicenter clinical trial, data from all study centers will be 
pooled and analyzed for a primary publication of the study results. The sponsor will coordinate and prepare this primary publication. The investigator agrees that the primary publication, which 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 76 of 91  Version 4 (16 October  2020)  will be coor dinated by the sponsor, will be the first publication to present the pooled study 
results. Other ancillary publications or presentations relating to the pooled data from this study 
may be suggested by the investigator but  can only be published with the express consent of the 
sponsor and the other investigators; such ancillary publications will also be coordinated by the sponsor.  
After the primary publication, or if the primary publication is not published within 2 years of 
termination of the study, the investigator may freely publish or present the results of his or her work conducted under the clinical trial agreement, subject to providing the sponsor with the opportunity to review the contents of any proposed presentation, abstract, or publication about such work, including any results of this study, in advance of any presentation or submission for publication. Within that advance notice period, the sponsor may review the proposed publication to identify patentable subjec t matter and/or any inadvertent disclosure of its confidential 
information, which must be redacted from any final publication or presentation. If necessary, to permit the preparation and filing of patent applications, the sponsor may elect an additional review period. The durations of the review periods will be specified in contractual agreements 
between each study center and the sponsor.  
In most cases, the principal investigators at the study centers with the highest accruals of eligible subjects and/or who have provided significant intellectual input into the study design, shall be listed as lead or senior authors on publications and presentations of study results. Sponsor clinical personnel, lead statistician, scientific personnel, or other staff members meeting the 
requirements for authorship may also be included in the list of authors. This custom can be adjusted upon mutual agreement of the authors and the sponsor. 
13.19. Study Discontinuation  
Both the investigator and the sponsor reserve the right to terminate the study at any time. Should 
this be necessary, both parties will arrange discontinuation procedures. The investigator will be 
responsible for notifying the relevant study center IRB/IEC. The sponsor will be responsible for 
notifying the appropriate regulatory authorities. In terminating the study, the investigator and the sponsor will assure that adequate consideration is given to the protection of the subjects’ interests.  As directed by the sponsor, all study materials must be collected and all eCRFs 
completed to the greatest extent possible.  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 77 of 91  Version 4 (16 October  2020)  14. BIBLIOGRAPHY 
Carette JE, Raaben M, Wong AC, Herbert AS, Obernosterer G, Mulherkar N, Kuehne AI, 
Kranzusch PJ, Griffin AM, Ruthel G, Dal Cin P, Dye JM, Whelan SP, Chandran K, 
Brummelkamp TR. Ebola virus entry requi res the cholesterol transporter Niemann -Pick C1. 
Nature. 2011 Aug 24;477(7364):340-3. doi: 10.1038/nature10348. PMID: 21866103. 
Carpenter, JR; Kenward, MG; (2007) Missing data in randomised controlled trials: a practical 
guide. Health Technology Assessment Methodology Programme, Birmingham, p. 199. https://researchonline.lshtm.ac.uk/id/eprint/4018500.   
Clinical Trials Facilitation Group (CTFG). Recommendations related to contraception and 
pregnancy testing in clinical trials. 2014 Sep 15. Available at: http://www.hma.eu/fileadmin/dateien/Human_Medicines/01 -
About_HMA/Working_Groups/CTFG/2014_09_HMA_CTFG_Contraception.pdf  (accessed . 
2019 Dec 17). 
Food and Drug Administration (FDA). Drug development and drug interactions: T able of 
substrates, inhibitors and inducers. 2020 Mar 10. Available at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProce ss/DevelopmentResources/DrugInteractio
nsLabeling/ucm093664.htm#4  
Ge M, Durham L.K., Meyer R.D., Xie W, Thomas N. “Covariate Adjusted Difference in 
Proportions from Clinical Trials Using Logistic Regression and Weighted Risk Difference” Drug 
Information Journal 2011 45: 481-493. https://doi.org/10.1177/009286151104500409 
Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. 
The New England journal of medicine. 2020 82:1708-1720. DOI: 10.1056/NEJMoa2002032 
Kang YL, Chou YY, Rothlauf PW, Liu Z, Piccinotti S, Soh TK, Cureton D, Case JB, Chen RE, 
Diamond MS, Whelan SPJ, Kirchhausen T. Inhibition of PIKfyve kinase prevents infection by 
EBOV and SARS -CoV-2. bioRxiv. doi: https://doi.org/10.1101/2020.04.21.053058. 2020 Apr 
Preprint  
Lachin JM.  Statistical considerations in the intent- to-treat principle. Controlled Clinical Trials. 
2000 21:167-89. 
Lan, K.K.G. and DeMets, D.L. 'Discrete sequential boundaries for clinical trials.' Biometrika, 
1983 70, pages. 659-663. 
Lauer SA, Grantz KH, Bi Q, et al. The Incubation Period of Coronavirus Disease 2019 
(COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Annals of 
internal medicine. 2020.  
Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine. 2020. 
Murray JL, Mavrakis M, McDonald NJ, Yilla M, Sheng J, Bellini WJ, Zhao L, Le Doux JM, 
Shaw MW, Luo CC, Lippincott- Schwartz J, Sanchez A, Rubin DH, Hodge TW. Rab9 GTPase is 
required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus. 
J Virol. 2005 Sep;79(18):11742- 51. PMID : 16140752 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 78 of 91  Version 4 (16 October  2020)  National Research Council.  “The Prevention and Treatment of Missing Data in Clinical Trials.  
Panel on Handling Missing Data in Clinical Trials”.  Committee on National Statistics, Division 
of Behavioral and Social Sciences and Education.  Washington, DC: The National Academies 
Press, 2010. 
Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, 
DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, Xu X, 
Wang A, Hughes E, Martin S, Thomas C, Jahrling PB, Hensley LE, Olinger  GG Jr , White JM. 
The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and 
infection. PLoS Negl Trop Dis. 2017 Apr 12;11(4):e0005540. PMID: 28403145 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. Toxicity and respons e criteria of 
the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. 
Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, Xiang Z, Mu Z, Chen X, 
Chen J, Hu K, Jin Q, Wang J, Qian Z. Characterization of spike glycoprote in of 2019-nCoV on 
virus entry and its immune cross -reactivity with spike glycoprotein of SARS -CoV. Nat 
Communications. 2020 Feb. Under Review  
Qiu, S., Leung, A., Bo, Y. et.al. Ebola virus requires phosphatidylinositol (3,5) bisphosphate 
production for efficient viral entry Virology, 2018, 513 17-28 
Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Burgstaller-Muehlbacher S, Pache L, 
De Jesus PP, Hull MV, Chang M, Chan JFW, Cao J, Poon VKM, Herbert K, Nguyen TT, Pu Y, Nguyen C, Rubanov A, Martinez-Sobrido L, Liu WC, Miorin L, White KM, Johnson JR, Benner 
C, Sun R, Schultz PG, Su A, Garcia- Sastre A, Chatterjee AK, Yuen K -Y, Chanda S K. A Large -
scale Drug Repositioning Survey for SARS -CoV -2 Antivirals. bioRxiv. doi: 
https://doi.org/10.1101/2020.04.16.044016. 2020 Apr Preprint 
Smith GB, Prytherch DR, Meredith P, Schmidt PE. Early warning scores: unravelling detection 
and escalation. Int J Health Care Qual Assur 2015;28:872–5. 
Wada Y, Lu R, Zhou D, Chu J, Przewloka T, Zhang S, Li L, Wu Y, Qin J, Balasubramanyam V, 
Barsoum J, Ono M. Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 
inhibitor. Blood. 2007 Feb 1;109(3):1156-1164. 
Wada Y, Cardinale I, Khatcherian A, Chu J, Kantor AB, Gottlieb AB, Tatsuta N, Jacobson E, 
Barsoum J, Krueger JG. Apilimod inhibits the production of IL -12 and IL-23 and reduces 
dendritic cell infiltration in psoriasis. PLoS One. 2012;7(4):e35069. PMID: 22493730 
WHO Master Protocol , 2020. “A Multi-center, Adaptive, Randomized, Double- Blind, Placebo-
Controlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the 
Treatment of COVID-19 in Hospitalized Subjects.” 
Woosley RL, Romero KA. Qtdrugs List, 2015 Jul 3, AZ CERT, Inc., Available at: 
www.Crediblemeds.org www.Crediblemeds.org  (accessed 27 Dec 201 8). 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 79 of 91  Version 4 (16 October  2020)  15. APPENDICES 
15.1. Strong CYP3A Inhibitors and Inducers  
Effect on CYP3A  Drug  
Strong CYP3A Inhibitors  boceprevir, cobicistat, danoprevir and ritonavir, elvitegravir and ritonavir, 
grapefruit juice, indinavir and ritonavir, itraconazole, ketoconazole, lopinavir and 
ritonavir, paritaprevir and ritonavir and (ombitasvir and/or dasabuvir), posaconazole, ritona vir, saquinavir and ritonavir, telaprevir, tipranavir and 
ritonavir), telithromycin, troleandomycin, voriconazole  
Strong CYP3A Inducers  apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, 
St. John’s wort  
Reference: [FDA 2020 ] 
Abbreviation:  CYP=cytochrome P450 enzyme  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 80 of 91  Version 4 (16 October  2020)  15.2. Drugs Known to Prolong the QT Interval and/or Cause Torsades De Pointes  
Generic Name  Brand Names (Partial 
List)  Drug Class  Therapeutic Use  
Amiodarone  Cordarone®, Pacerone®, 
Nexterone®  Antiarrhythmic  Abnormal heart rhythm  
Anagrelide  Agrylin®, Xagrid®  Phosphodiesterase 3 
inhibitor  Thrombocythemia  
Arsenic trioxide  Trisenox®  Anticancer  Cancer (leukemia)  
Astemizole (removed 
from market)  Hismanal®  Antihistamine  Allergic rhinitis  
Azithromycin  Zithromax®, Zmax®  Antibiotic  Bacterial infection  
Bepridil (removed 
from market)  Vascor®  Antianginal  Angina Pectoris (heart pain)  
Chloroquine  Aralen®  Antimalarial  Malaria  
Chlorpromazine  Thorazine®, Largactil®, 
Megaphen®  Antipsychotic / 
Antiemetic  Schizophrenia, nausea, many 
others  
Cilostazol  Pletal®  Phosphodiesterase 3 
inhibitor  Intermittent claudication  
Ciprofloxacin  Cipro®, Cipro -XR®, 
Neofloxin®  Antibiotic  Bacterial infection  
Cisapride (removed 
from market)  Propulsid®  Gastrointestinal  
stimulant  Increase gastrointestinal 
motility  
Citalopram  Celexa®, Cipramil®  Antidepressant, 
selective serotonin 
reuptake inhibitor  Depression  
Clarithromycin  Biaxin®, Prevpac®  Antibiotic  Bacterial  infection  
Cocaine  Cocaine  Local anesthetic  Anesthesia (topical)  
Disopyramide  Norpace®  Antiarrhythmic  Abnormal heart rhythm  
Dofetilide  Tikosyn®  Antiarrhythmic  Abnormal heart rhythm  
Domperidone (only 
on non -US market)  Motilium®, Motillium®, 
Motinorm Costi®, 
Nomit®  Antinausea  Nausea, vomiting  
Donepezil  Aricept®  Cholinesterase 
inhibitor  Dementia (Alzheimer’s 
Disease)  
Dronedarone  Multaq®  Antiarrhythmic  Abnormal heart rhythm  
Droperidol  Inapsine®,  Droleptan®,  
Dridol®,  Xomolix®  Antipsychotic / 
Antiemetic  Anesthesia (adjunct), nausea  
Erythromycin  E.E.S.®, Robimycin®, 
Emycin®, Erymax®, Ery -
Tab®, Eryc Ranbaxy®, 
Erypar®, Eryped®, Erythrocin Stearate Filmtab®, Erythrocot®,  
E-Base®, Erythroped®, 
Ilosone®, MY -E®, 
Pediamycin®, Zineryt®,  
Abboticin®, Abboticin -
ES®, Erycin®, PCE Dispertab®, Stiemycine®, 
Acnasol®, Tiloryth®  Antibiotic  Bacterial infection, increase 
gastrointestinal motility  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 81 of 91  Version 4 (16 October  2020)  Generic Name  Brand Names (Partial 
List)  Drug Class  Therapeutic Use  
Escitalopram  Cipralex®, Lexapro®, 
Nexito®, Anxiset -E® 
(India), Exodus® (Brazil), 
Esto® (Israel), Seroplex®, 
Elicea®, Lexamil®, 
Lexam®, Entact® (Greece), Losita® 
(Bangladesh), Reposil® 
(Chile), Animaxen® 
(Colombia), Esitalo® 
(Australia), Lexamil® 
(South Africa)  Antidepressant, 
selective serotonin reuptake inhibitor  Depression (major) , anxiety 
disorders  
Flecainide  Tambocor®, Almarytm®, 
Apocard®, Ecrinal®, 
Flécaine®  Antiarrhythmic  Abnormal heart rhythm  
Fluconazole  Diflucan®, Trican®  Antifungal  Fungal infection  
Gatifloxacin 
(removed from 
market)  Tequin®  Antibiotic  Bacterial infection  
Grepafloxacin  Raxar®  Antibiotic  Bacterial infection  
Halofantrine  Halfan®  Antimalarial  Malaria  
Haloperidol  Haldol® (US & UK), 
Aloperidin®, Bioperidolo®, Brotopon®, 
Dozic®, Duraperidol® 
(Germany), Einalon S®, Eukystol®, Halosten®, 
Keselan ®, Linton®, 
Peluces®, Serenace®, 
Serenase®, Sigaperidol®  Antipsychotic  Schizophrenia, agitation  
Ibogaine (only on 
non-US market)  None  Psychedelic  Narcotic addiction, unproven  
Ibutilide  Corvert®  Antiarrhythmic  Abnormal heart rhythm  
Levofloxacin  Levaquin® , Tavanic®  Antibiotic  Bacterial infection  
Levomepromazine 
(methotrimeprazine)  
only on non- US 
market)  Nosinan®, Nozinan®, 
Levoprome®  Antipsychotic  Schizophrenia  
Levosulpiride (only 
on non -US market)  Lesuride®, Levazeo®. 
Enliva® (with rabeprazole)  Antipsychotic  Schizophrenia  
Levomethadyl 
acetate (removed 
from market)  Orlaam®  Opioid agonist  Narcotic dependence  
Mesoridazine 
(removed from 
market)  Serentil®  Antipsychotic  Schizophrenia  
Methadone  Dolophine®, Symoron®, 
Amidone®, Methadose®, 
Physeptone®, Heptadon®  Opioid agonist  Narcotic dependence, pain  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 82 of 91  Version 4 (16 October  2020)  Generic Name  Brand Names (Partial 
List)  Drug Class  Therapeutic Use  
Moxifloxacin  Avelox®, Avalox®, 
Avelon®  Antibiotic  Bacterial infection  
Ondansetron  Zofran®, Anset®, 
Ondemet®, Zuplenz®, 
Emetron®, Ondavell®, Emeset®, Ondisolv®, 
Setronax®  Antiemet ic Nausea, vomiting  
Oxaliplatin  Eloxatin®  Antineoplastic 
Agent  Cancer  
Papaverine HCl  none  Vasodilator, 
Coronary  Diagnostic adjunct  
Pentamidine  Pentam®  Antifungal  Fungal infection 
(Pneumocystis pneumonia)  
Pimozide  Orap®  Antipsychotic  Tourette’s Disorder  
Probucol (removed 
from market)  Lorelco®  Antilipemic  Hypercholesterolemia  
Procainamide  Pronestyl®, Procan®  Antiarrhythmic  Abnormal heart rhythm  
Propofol  Diprivan®, Propoven®  Anesthetic, general  Anesthesia  
Quinidine  Quinaglute®, Duraquin®, 
Quinact®, Quinidex®, 
Cin-Quin®, Quinora®  Antiarrhythmic  Abnormal heart rhythm  
Roxithromycin (only 
on non -US market)  Rulide®, Xthrocin®, 
Roxl -150®, Roxo®, 
Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, 
Roxomycin®, Rulid®, 
Tirabici n®, Coroxin®  Antibiotic  Bacterial infection  
Sevoflurane  Ulane®, Sojourn®  Anesthetic, general  Anesthesia  
Sotalol  Betapace®, Sotalex®,  
Sotacor®  Antiarrhythmic  Abnormal heart rhythm  
Sparfloxacin 
(removed from 
market)  Zagam®  Antibiotic  Bacterial infection  
Sulpiride (only on 
non-US market)  Dogmatil®, Dolmatil®, 
Eglonyl®, Espiride®, 
Modal®, Sulpor®  Antipsychotic, 
atypical  Schizophrenia  
Sultopride (only on 
non-US market)  Barnetil®, Barnotil®, 
Topral®  Antipsychotic, 
atypical  Schizophrenia  
Terfenadine 
(removed from 
market)  Seldane®  Antihistamine  Allergic rhinitis  
Terlipressin (only on 
non-US market)  Teripress®, Glypressin®, 
Terlipin®, Remestyp®, Tresil®, Teriss®, and 
others  Vasoconstrictor  Septic shock  
Terodiline (only on 
non-US market)  Micturin®, Mictrol® (not 
bethanechol)  Muscle relaxant  Bladder spasm  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 83 of 91  Version 4 (16 October  2020)  Generic Name  Brand Names (Partial 
List)  Drug Class  Therapeutic Use  
Thioridazine  Mellaril®, Novoridazine®, 
Thioril®  Antipsychotic  Schizophrenia  
Vandetanib  Caprelsa®  Anticancer  Cancer (thyroid)  
Note:  Includes those drugs known to prolong the cardiac QT interval or cause TdP ( Woosley  2018> 8 
days8). 
Abbreviation:  QT: Time of start of Q wave until end of T wave in the heart’s electrical cycle; TdP: 
Torsades de Pointes; UK: United Kingdom; US: United States  
 
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 84 of 91  Version 4 (16 October  2020)  15.3. ECOG Performance Status 
Grade  Description  
0 Fully active, able to carry on all pre -disease performance without restriction  
1 Restricted in physically strenuous activity but ambulatory and able to carry out 
work of a light or sedentary nature, e.g. light housework, office work 
2 Ambulatory and capable of all self -care but unable to carry out any work 
activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair  
5 Dead  
Reference: [Oken 1982 ] 
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 85 of 91  Version 4 (16 October  2020)  15.4. Protocol Amendment History  
15.4.1. Summary of Changes: Version 2 (10 July 2020) 
 Overall Rationale for the Amendment  
This amendment clarifies wording in the 22 June 2020 version of the clinical protocol and 
addresses requests received from the FDA following FDA review of the 22 June 2020 version of the clinical protocol.  
 Description of Changes 
Section or Table Number  Description of Change  Brief Rationale  
Various sections  • Changes  to protocol versions and dates were 
made  
• Minor typographical, syntax, or formatting corrections were made  To make appropriate editorial modifications  
Table 1: Schedule of Activities  
3.1 Primary Objective  
3.2 Secondary Objectives  
4.1 Primary Endpoint  
4.2 Secondary Endpoints  
4.3 Exploratory Endpoints  
5.1 Study Design  
5.4 Rationale for Study Design  
11 Efficacy Assessments  
12 Statistical Considerations  • Timing of sampling were clarified or updated  
• Assessment of mRNA from nasopharyngeal swab and saliva on Day 28 was added  
• Cytokine analysis on Day 4 was added 
• Definition of clinical status endpoint was corrected 
• Definition of oxygen saturation endpoint was corrected 
• SARS -CoV -2 viral load endpoints relating 
to nasopharyngeal and salivary samples were added or clarified  
• Definition of cytokine endpoint was corrected 
• Definition of viral genome sequence endpoint was corrected  To ensure consistency of assessment and to address FDA requests  
Table 1: Schedule of Activities  • Instructions regarding timing of screening 
ECG, hematology testing, and serum chemistry testing were modified  To define allowable 
screening window for these 
tests 
Table 1: Schedule of Activities  • Requirements for fasting during pharmacokinetic assessments were included  To ensure  consistency of 
fed-fasting status during 
pharmacokinetic evaluations  
6.1 Inclusion Criteria  • Modified definition of symptoms of mild COVID -19 disease To provide clarification  
Table 1: Schedule of Activities 8.1. Supportive Care  • Discussion of use of illicit drugs removed  To delete unneeded text  
9.1.2 Serious Adverse Event  • Text was modified to indicate that deaths 
due to COVID -19 (rather than cancer 
progression) may be defined as SAEs  To correct SAE definition  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 86 of 91  Version 4 (16 October  2020)  Section or Table Number  Description of Change  Brief Rationale  
9.7.2 Pregnancy  • Reporting requirements for pregnancy in 
female partners of male subjects were 
updated  To ensure timely reporting of such occurrences  
12.4.5 Exploratory Endpoints  • Erroneous reference to exploratory objectives was removed and analyses were referenced to the SAP or separate reports  To clarify plan for analyses of exploratory endpoints 
12.4.10 Other Analyses  • Section was removed  To delete unneeded text  
13.11 Study Drug Accountability  • Instructions for recording of bottle numbers 
were included  
• Instructions for disposition of study drug were updated  To clarify appropriate procedures for study drug accountability  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 87 of 91  Version 4 (16 October  2020)  15.4.2. Summary of Changes: Version 3 (31 August 2020) 
 Overall Rationale for the Amendment  
This amendment incorporates the following changes to the protocol.  
 Description of Changes 
Section or Table Number  Description of Change  Brief Rationale  
Various sections  • Changes  to protocol versions and dates were 
made  
• Minor typographical, syntax, or formatting 
corrections were made  
• Changes in the synopsis were made consistent with changes to the body of the protocol document  To make appropriate editorial modifications  
Table 1: Schedule of Activities  • Instructions were included to described activities to be performed in a subject terminating from the study prematurely 
• The timing of the LAM -002A compliance 
checks was clarified  
• Incorrect mention of urinalysis was removed from the table  
• It was indicated that screening and baseline visits could occur on the same day. 
• Instructions for drug dispensing were clarifi ed 
• It was indicated that subjects taking only a single dose of study drug on Day 1 due to initiation late in the day should continue 
drug through Day 11 in order to ensure 
completion of a full 20 doses of study drug administration.  
• It was indicated that co mpliance would be 
assessed at each visit throughout the dosing period . 
• To enhance flexibility in study conduct, it was noted that obtaining nasopharyngeal 
swabs on Days 6 and 8 would be optional; 
saliva would still be collected at these time 
points, thus a llowing an alternative and 
better tolerated evaluation of viral load  To provide appropriate direction to investigational personnel  
2.1 Study Rationale  
5.1 Study Design  
6.1 Inclusion Criteria (Number 4)  • The permissible duration of COVID -19 
symptoms before study enrollment was increased from 4 days to 8 days  To permit greater flexibility in prestudy symptom duration to 
enhance ease of subject 
enrollment. 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 88 of 91  Version 4 (16 October  2020)  Section or Table Number  Description of Change  Brief Rationale  
3 Study Objectives  
4 Study Endpoints  
5.Study Design  
11 Efficacy Assessments  
12 Statistical Considerations  • Multiple sections of the protocol were 
modified to indicate that that the study 
would focus on analyzing subjects with a 
baseline viral load of >105 copies/mL; 
accordingly, the total sample size was 
increased to ~2 84 subjects to ensure accrual 
of the sample of  ~142 subjects with 
baseline viral load of >105 copies/mL 
required to perform the analysis consistent 
with the primary hypothesis of the study  
• An antiviral efficacy analysis population consisting of all randomized subjects with a baseline viral load >10
5 copies/mL was 
added  
• Clarifications were provided regarding the populations (ITT, Antiviral Efficacy, PP) to be analyzed for each endpoint  To ensure that there would be sufficient subjects wit h 
an adequate viral load to allow evaluation of LAM -002A  effects and to 
update and clarify the populations in which specific analyses would be performed  
6.1 Inclusion Criteria (Number 3)  • The types and specificity of the descriptions of permissible symptoms of COVID -19 
necessary for study enrollment was enhanced  To improve clarity and enhance enrollment potential  
8.2.3 Dose Schedule Interruptions 
and Vomited Doses  • It was indicated that subjects taking only a single dose of study drug on Day 1 due to 
initiation late in the day could skip taking a 
2
nd dose on that day, could resume study 
drug administration on the morning of Day 2 
and continue drug through Day 11 in order 
to ensure completion  of a full 20 doses of 
study drug administration.  To provide clarification to study center personnel and 
study subjects regarding 
permitted variations in the dosing schedule  
12.4.7 Plan for Missing Data  • The reasons for not considering a subject for 
analy sis were updated to include a false 
positive test for SARS -CoV -2 (in additional 
to withdrawal of consent or lost to follow -
up). To clarify the analysis plan  
14 Bibliography  • An explanatory reference was added  To document the approach 
to logistic regression analysis  
  
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 89 of 91  Version 4 (16 October  2020)  15.4.3. Summary of Changes: Version 4 (16 October 2020) 
 Overall Rationale for the Amendment  
This amendment incorporates the following changes to the protocol.  
 Description of Changes 
Section or Table Number  Description of Change  Brief Ration ale 
Various sections  • Changes  to protocol versions and dates were 
made. 
• Minor typographical, syntax, or formatting 
corrections were made. 
• Changes in the synopsis were made consistent with changes to the body of the protocol document . To make appropriate 
editorial modifications  
Table 1: Schedule of Activities  • Day 6 and 8  were changed to remote visits.  
• Footnote d of the Schedule of Activities was 
added to clarify an optional provision for a 
confirmatory viral test for those who do not 
have a documentation of a positive test . 
• Vital signs /oxygen saturation on Days 6 and 
Days 8 were removed  in Footnote i.  
• Telehealth visits on Days, 6, 8 and 22 were 
noted in the Schedule of Activities table 
header.  
• Footnote  j was clarified to indicate that the 
AE review on Days 6, 8 and 22 will be via 
telehealth/telephone . 
• Footnote k was changed to indicate that the 
concomi tant medication review on D ays, 6, 
8 and 22 will be via telehealth/telephone . 
•  Footnote r was added regarding subject 
COVID -19 symptoms diary . 
• Footnote v was added for saliva sample 
collection on Days 1, 4 , 11, and 28. To provide appropriate direction to investigational personnel  
Section 1: Protocol synopsis  • The s econdary objective for antiviral 
assessment  from nasopharyngeal samples on Day s 11 and  28 were removed. 
• The s econdary objective for assessment of 
O
2 saturation was c hanged from Days 1, 4, 
6, 8 and 11  to Days 1, 4, and 11 . 
• The e xploratory objective  for antiviral 
assessment was hanged from 
nasopharyngeal samples on Day 6 to saliva samples on Day 4. 
• The e xploratory objective for antiviral 
assessment using nasopharyngeal  samples 
on Day 8 was changed to saliva samples on 
Day 11 . To provide appropriate direction to investigational personnel . 
To clarifies timing of 
antiviral assessments and 
the type of sample 
(whether nasopharyngeal 
vs saliva ). 
To add an alternative 
nasopharyngeal endpoint . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 90 of 91  Version 4 (16 October  2020)  Section or Table Number  Description of Change  Brief Ration ale 
• A separate exploratory objective for saliva 
antiviral assessment was specified at 
Day  28. 
• An a ntiviral assessment in saliva samples 
based on AUC analysis added  
• An exploratory a nti-viral assessment was 
added based on the difference in the 
proportion of subjects with SARS -CoV -2 
viral load <LLOQ between the LAM -002A 
and the placebo as measured by a qRT -PCR 
test from nasopharyngeal samples at Day 4. 
• A requirement was added for written 
documentation of SARS -CoV-2 infection 
via a validated test . 
Section 3 : Study Objectives  • Secondary and exploratory objectives were 
revised to align to objectives in synopsis 
(Section 1) To align study objectives 
with those in the synopsis  
Section 4: Study Endpoints  • Primary endpoint: Added clarifying language around quantitation of viral load  
• Secondary Endpoint  for antiviral assessment  
from nasopharyngeal samples on Days 11 
and 28, and by AUC analysis  was removed  
• Secondary Endpoint for assessment of O
2 
saturation was changed from Days 1, 4, 6, 8 
and 11 to Days 1, 4, and 11 . 
• Exploratory endpoints  for assessment of  
viral load from nasopharyngeal samples at Day 6 and Day 8 were removed . 
• The endpoint of difference in proportion of 
subjects with SARS -CoV -2 viral load 
<LLOQ between the LAM -002A and the 
placebo as measured by a qRT- PCR test 
from nasopharyngeal samples at Day 4 arm 
was added.  To clarify changes in study 
endpoints  and add an 
alternative  exploratory 
endpoint  
Section 5.1 Study Design • Paragraph 1: Text was added regarding  
asymptomatic subjects  with a positive test . 
• Paragraph 2: Information was added regarding randomization via a central ized 
randomization system. 
• Paragraph 2: Stratification by site was 
removed.  To allow flexibility in randomization  
Section 5.2 Study Conduct  • Paragraph 3 : It was clarified that a CRO 
other than Yale University  could become 
involved in conduct of the study.  To permit alternatives approaches to operational 
coordination  
Section 6.1 Inclusion Criteria  • The need for written documentation of a 
positive test  was included.  To include more 
outpatients and document 
positive infection . 
Investigational Drug: LAM-002A  
Study Protocol: LAM -002A-CVD-CLN01 AI Therapeutics, Inc.  
CONFIDENTIAL  Page 91 of 91  Version 4 (16 October  2020)  Section or Table Number  Description of Change  Brief Ration ale 
• Text was added to allow for inclusion of 
asymptomatic patients . 
Section 7.1 Randomization  • Text was added to accommodate more 
clinical sites . To provide additional 
operational flexibility  
Section 8.1.4 Shipping Storage and Stability  • Paragraph 2: Reference to Yale University 
was replaced with more general language to 
add operational flexibility  To clarify change in 
operational coordination  
Section 9.7.3  • Management  of contact information for 
SAEs and pregnancy was changed from 
Yale University to a CRO  To clarify change in 
operational coordination  
Section 10.1 Laboratory and Other Parameters to be Assessed  • A footnote was added to Table 6  
(Laboratory and Other Parameters to be 
Assessed) , clarifying th at samples for these 
exploratory endpoints will be collected but analysis of the samples is optional  To provide clarity to investigation personnel  
Section 10.1 Methods and Analytes  • Paragraph s were added to clar ify method of 
viral load measurements  and limits of 
detection (LLOQ) , details of 
pharmacodynamic and biomarker measurements , and optional nature of some 
assays  To provide clarity to investigation personnel  
Section 11.1  • Additional text was added to define the 
analysis of primary endpoint  To provide clarity on endpoint  
Section 12 Statistical Considerations  • Paragraph 2 : stratification by site was 
removed.  
• Change s in statistical parameters  were 
incorporated.  To clarify stratification  and 
adjust statistical analysis  
Section 12.4.4 Analysis of Secondary Outcomes  • The s econdary endpoint for analysis of 
nasopharyngeal viral load analysis at Day 11 and by AUC
Day1-Day11  was removed.  
• It was sp ecified that analys es of secondary 
endpoints  will be in the antiviral efficacy 
analysis population (population with viral load >10
5 copies/mL). To provide clarity to investigation personnel  
To clarify the statistical 
analysis population for secondary endpoints  
Section 12.5 Interim Analyses  • Potential DSMB decisions regarding 
interim analyses were updated.  To clarify statistical 
analysis population for interim analysis . 
Section 14 Bibliography  • The Carpenter et al. reference was added.  To provide support for the 
statistical approach . 
 